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91. INTRODUCTION 
1.1 Hyperbilirubinemia, neonatal jaundice and kernicterus
Hyperbilirubinemia is defined as an abnormally high concentration of bilirubin in the 
circulating blood. A wide definition of hyperbilirubinemia in the newborn is the one of a total
serum bilirubin (TSB) concentration in excess of the normal adult upper limit of 22 to 26 
μmol/L (Gartner, 1994). As the TSB level of healthy term infants peaks at approximately 100 
μmol/L, a more useful definition of hyperbilirubinemia might be a TSB level that exceeds the 
95th percentile for the infants age in hours (Maisels, 2006). In the newborn, bilirubin in the 
blood stream and tissues is almost exclusively present as unconjugated bilirubin. This is 
converted to conjugated bilirubin in the liver and excreted into bile. Unconjugated bilirubin 
may exist in the blood stream as albumin-bound bilirubin or as bilirubin not bound to 
albumin, labelled free or unbound bilirubin. In the newborn a visible yellowish staining of the 
sclera and skin, icterus or neonatal jaundice, results from an increase in TSB beyond 80 - 
100μmol/L (Gartner, 1994), which is present in almost two thirds of all newborns during the 
first week of life (Maisels, 1999). This so-called physiologic jaundice of the newborn is a 
transient phenomenon caused by a set of normal developmental features during the newborn 
period.
Bilirubin is toxic to the central nervous system and may cause a sequence of 
neurological symptoms and signs labelled acute bilirubin encephalopathy. A considerable 
proportion of these infants develops chronic bilirubin encephalopathy, a clinical tetrade 
consisting of movement disorders, auditory dysfunction, oculomotor impairments, and dental 
enamel hypoplasia of the deciduous teeth (Volpe, 2003). The clinical sequel in these infants 
correspond to the pathologic-anatomic localisation of the lesions in the basal ganglia, auditory 
brainstem nuclei, and brainstem oculomotor nuclei (Volpe, 2003). The bilirubin staining of 
the basal nuclei in the brain has given rise to the term kernicterus (Schmorl, 1904). Although 
kernicterus is a pathologic-anatomic term, it is often used to describe the associated clinical 
findings. There is evidence that less severe hyperbilirubinemia can produce more subtle, 
chronic encephalopathy referred to as bilirubin-induced neuronal dysfunction (BIND) 
(Johnson et al., 2002). A BIND scoring scale has been proposed as a tool to objectify the 
neonatal neurological exam, however, this BIND score has not been validated (Shapiro, 
2005). In the present thesis kernicterus is used as the term to describe the whole spectrum of 
permanent bilirubin-induced clinical sequel. For “unconjugated bilirubin”, “bilirubin” is used. 
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1.2 A brief review of the history of kernicterus 
Kernicterus was long considered to be a specific sequel of Rh immunization. Convincing 
evidence of an association between hyperbilirubinemia and kernicterus was first reported in 
the early 1950`s, when Hsia et al introduced guidelines based on serum bilirubin levels for 
the management of infants with Rh immunization (Hsia et al., 1952;Hsia et al., 1953). The 
authors stated that kernicterus was unlikely to occur when the TSB remained below 340 
μmol/L (20 mg/100 ml), which remains an important perception in the treatment of 
hyperbilirubinemia in the term infant. However, observations from 1950’s reporting that 
premature birth was associated with increased risk of kernicterus, even in the absence of 
extreme hyperbilirubinemia (“low bilirubin kernicterus”), suggested a more complex 
relationship between hyperbilirubinemia and kernicterus (Harris et al., 1958).
The prevention of Rh (D) sensitization in Rh-negative mothers by postpartum 
prophylaxis with Rh immunoglobulin greatly reduced the incidence of kernicterus (Volpe JJ, 
2003). Exchange transfusion to reduce the level of unconjugated bilirubin in the bloodstream 
was introduced by Wallerstein in 1946 (Wallerstein, 1946). In the 1950’s an English nurse 
observed that the skin of a jaundiced infant who had been exposed to sunlight had faded, 
leading to the discovery of the principle of photo-conversion of bilirubin (Cremer et al., 1958) 
and to the introduction of phototherapy in the 1960’s. With improved neonatal care, the 
prevention of Rh (D) sensitization, and the possibility to detect and treat infants at risk, 
kernicterus almost disappeared in the developed world during the 1970’s. A declining number 
of cases of kernicterus were reported in preterm babies, and very few cases of kernicterus 
were reported in term or near term infants in the 1970’s and 1980’s (Ebbesen, 2000;Hansen, 
2000b;Johnson et al., 2002). 
Recently there has been an apparent resurgence of kernicterus in the 
industrialized world. In Denmark no cases of kernicterus were reported from the early 1970’s 
till 1994, but between 1994 and 1998 six cases were reported (Ebbesen, 2000). In response to 
anecdotal reports of kernicterus in term and near term infants a Pilot Kernicterus Register for 
the US was established in 1992 (Johnson et al., 2002). By 2002, 90 infants had been enrolled 
in the registry, and by 2004 125 cases had been identified (Bhutani et al., 2004). The reason 
for this resurgence of kernicterus is uncertain, but both early postnatal discharge and loss of 
concern about jaundice in full term infants may be implicated (Brown & Johnson, 
1996;Ebbesen, 2000). It should be kept in mind that outside the industrialized world the 
picture is different. In parts of sub-Saharan Africa kernicterus has been reported in up to 20 % 
of severely jaundiced infants born outside hospital (Ahmed et al., 1995). In children with 
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cerebral palsy the proportion of children thought to be suffering from the effects of 
kernicterus has been estimated to be as high as 50 % (2 - 50 %) in third world countries 
(Egdell & Stanfield, 1972).
1.3 The clinical problem 
Hyperbilirubinemia is the most commonly treated condition in newborn medicine. In a survey 
by Atkinson et al approximately 7 % of all newborns met the criteria for phototherapy 
(Atkinson et al., 2003). In Canada severe hyperbilirubinemia is the most common cause of 
neonatal readmission to hospital (Sgro et al., 2006). In otherwise healthy infants without 
predisposing factors for hyperbilirubinemia TSB levels as high as 340 - 450 ȝmol/L can occur 
due to physiologic processes during the first days of life (Gartner, 1994), and in most cases 
the underlying cause of hyperbilirubinemia can not be identified (Sgro et al., 2006;Tiker et
al., 2006). 31 % of the infants enrolled in the Pilot Kernicterus Register had no detectable 
cause for their hyperbilirubinemia and were classified as idiopatic (Johnson et al., 2002). 
Still, most otherwise healthy infants with TSB levels exceeding 340 ȝmol/L are not likely to 
develop cerebral damage even in the absence of treatment (Bengtsson & Verneholt, 
1974;Killander et al., 1963). Hence, a TSB level exceeding 340 ȝmol/L in an otherwise 
healthy, term infant, is a poor marker to identify newborns at risk of developing kernicterus. 
Long duration of hyperbilirubinemia has been reported to be an important risk 
factor for developing kernicterus (Devries et al., 1985;Ozmert et al., 1996), however, duration 
of exposure is not included in current treatment guidelines. More specific and clinically useful
markers of the risk of subsequent kernicterus such as the level of unbound or free bilirubin, 
which is supposed to cross the blood-brain barrier (BBB) more readily than albumin-bound 
bilirubin (Ahlfors, 2000;Wennberg, 2000), or bilirubin-induced changes in brainstem auditory 
evoked potential (BAEP) (Shapiro, 1988;Shapiro, 2003) have been proposed. To date, the 
usefulness of these markers in determining which infants are at risk of developing kernicterus 
is uncertain.  
At physiologic and slightly higher concentrations (low nanomolar 
concentrations) bilirubin is considered to be protective against oxidative stress (Baranano et
al., 2002;Dore et al., 1999). The antioxidant properties have been associated with a decreased 
risk of atherosclerotic disease (Sedlak & Snyder, 2004). It has repeatedly been claimed that 
hyperbilirubinemia is a necessary, but not sufficient condition to cause kernicterus. 
Additional risk factors may include diseases or disorders that increase the entry of bilirubin 
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into the brain such as asphyxia (Lucey et al., 1964) or meningitis (Pearlman et al., 1980). 
Also, the concomitant presence of factors such as hypoglycemia, metabolic aberrations or 
infection may enhance the susceptibility of the brain to bilirubin (Volpe, 2003). However, in a 
review of 123 cases of kernicterus in infants  34 weeks gestation reported between 1955 and 
2001, 35 cases had no evidence of co-morbid factors (Ip et al., 2004a). Volpe states that 
“although the essential toxicity of bilirubin has been questioned, on the balance the weight of 
available data favours the notion that bilirubin per se is injurious to neurons” (Volpe, 2003). 
Recent findings suggest that even moderate hyperbilirubinemia may result in subtle, but 
possibly permanent, minor motor impairments (Grimmer et al., 1999;Ozmert et al.,
1996;Soorani-Lunsing et al., 2001). Minor motor impairments could, however, not be 
confirmed in a recent study in infants with TSB levels exceeding 428 ȝmol/L (Newman et al.,
2006).
Over the last two to three decades, changes in the standards of neonatal care 
such as an increase in the practice of breast feeding and early hospital discharge have taken 
place. Data from the Pilot Kernicterus Registry found that of 61 neonates with acute bilirubin 
encephalopathy during the first week of life, 59 were breast fed and 24 (39 %) had a weight 
loss of  >10 % of birth weight on admission (Johnson et al., 2002). A possible causal 
relationship between breastfeeding and kernicterus is not settled, but breastfeeding is 
associated with enhanced enterohepatic circulation of bilirubin and relative caloric 
deprivation (Watchko, 2005b).  
To summarize, there are no reliable, specific markers to identify which 
jaundiced infant is at risk of developing kernicterus. While clinical efforts such as pre-
discharge risk assessment and close follow-up monitoring after discharge hold promise for 
avoiding serious hyperbilirubinemia and kernicterus, important issues concerning bilirubin 
neurotoxicity await further clarification. These issues include 1) the relative contribution of 
albumin-bound and -unbound bilirubin to bilirubin toxicity, 2) the mechanism by which 
bilirubin enters the brain, 3) the preference of bilirubin for certain areas of the brain like the 
basal nuclei and the cerebellum, 4) whether bilirubin is, per se neurotoxic, or co-morbid 
factors are necessary to induce neurotoxicity, and 5) the molecular mechanisms by which 
bilirubin exerts its toxicity. As summarized by Ip et al in a comment on a recent evidence-
based review of neonatal hyperbilirubinemia: “Additional understanding of bilirubin 
neurotoxicity is clearly needed and may be forthcoming from basic science investigations” (Ip 
et al., 2004b).
13
2. ORIGIN, PHYSICAL PROPERTIES, AND KINETICS OF BILIRUBIN 
2.1 Bilirubin metabolism 
Bilirubin is formed in the organism as the end product of heme catabolism. The heme 
porphyrin ring is oxidized, producing carbon monoxide, iron and biliverdin. Biliverdin is then 
reduced to bilirubin primarily in the reticuloendothelial system (Maisels, 1999). In the blood 
stream bilirubin appears as a weak dianion that is almost insoluble in aqueous solutions at 
physiological pH, and to a large extent bound to albumin in the circulation (Brodersen, 
1979;Lightner et al., 1986). Reaching the parenchymal cells of the liver, bilirubin, but not 
albumin, crosses the cell membrane of the hepatocyte (Maisels, 1999). In the hepatozyte 
unconjugated bilirubin is converted to the water-soluble conjugated bilirubin by uridine 
diphosphoglucuronosyl transferase (UDPGT) and excreted into the bile (Maisels, 1999). 
Total bilirubin production per kg body weight during the first few days of life is about twice 
that of adults. As UDPGT activity is insufficient to handle the bilirubin load during these first 
days, bilirubin levels almost invariably increase. Due to a rapid increase in UDPGT activity, 
probably due to induction by bilirubin itself, bilirubin elimination from the circulation 
increases and serum bilirubin levels then fall (Maisels, 1999).  
2.2 Structure and solubility of bilirubin 
Spectroscopic studies have revealed that the bilirubin molecule is not planar as originally 
assumed, but rather has a folded ridge tail shape (Boiadjiev et al., 2004;Lightner et al., 1986). 
Stability is provided by intra-molecular hydrogen bonds which are responsible for its 
hydrophobicity, making it unexcretable in normal hepatic metabolism (Boiadjiev et al.,
2004). Phototherapy induces alterations in the structure of the bilirubin molecule principally 
by breaking the intra-molecular hydrogen bond of one of the propionic acids, causing the 
lipophilicity of the molecule to decrease and to allow intact excretion by the liver (Lightner & 
McDonagh, 2001). 
While the structure of the bilirubin molecule is well established, its aggregation 
is less well characterized. The solubility of bilirubin has been estimated to be as low as 7 
nmol/L based on bilirubin crystals in water (Brodersen, 1979) or 66 nmol/L based on its 
partitioning between water and chloroform (Hahm et al., 1992). It has been claimed that the 
higher value is more consistent with the values reported from serum of infants (Ostrow et al.,
1994). It is, however, possible that this high value may be erroneous due to the experimental 
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techniques used in these studies (Boiadjiev et al., 2004;Lightner et al., 1986). Under 
physiological conditions bilirubin does not aggregate in the blood due to its binding to 
albumin in the blood stream.  
Figure 1. Bilirubin structure: Left: linear representation with conventional numbering system; 
Right: the energetically more stable structure shaped like a ridge-tile (modified from 
Boiadjiev et al., 2004). 
2.3 Bilirubin, albumin, and the blood-brain barrier
Albumin has a binding affinity for bilirubin of 107-108 at its primary binding site for bilirubin, 
and one or two additional binding sites with much lower binding affinity (Brodersen, 
1979;Lightner et al., 1986). Only bilirubin which is not bound to albumin enters the brain by 
crossing an intact blood-brain barrier (BBB) (Maisels, 1999). Whether the fraction of 
bilirubin which actually enters the brain is derived exclusively from the fraction of unbound 
bilirubin or also from albumin-bound bilirubin in the blood stream is not finally settled. Even 
though the concentrations of unbound bilirubin rarely exceed 60 nM/L, even in jaundiced 
serum containing 100-300 ȝM/L TSB, it may be the principal driving force to achieve 
equilibrium between the different compartments (Wennberg, 1988;Wennberg, 2000). In the 
case of a rapid increase of bilirubin, as seen in the newborn infant, albumin serves as a 
biological buffer against bilirubin encephalopathy. Under certain conditions like excessive 
production of bilirubin due to hemolysis (Maisels, 1999;Volpe, 2003), in the presence of 
binding competitors for the bilirubin binding site of albumin (McDonald et al.,
1998;Silvermann et al., 1956), or reduced affinity of albumin to bilirubin as seen in sick and 
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preterm infants (Cashore, 1980), the binding capacity of albumin for bilirubin may be 
overwhelmed, allowing increased amounts of unbound bilirubin to enter the brain.
The permeability of the BBB to bilirubin may increase in certain diseases like 
meningitis (Pearlman et al., 1980) or asphyxia (Lucey et al., 1964). Opening of the BBB for 
bilirubin has been achieved by experimental induction of hypercarbia (Bratlid et al.,
1984;Wennberg et al., 1993) or hyperosmolarity (Ives et al., 1989;Wennberg et al., 1991). A 
study by Hansen et al examined the uptake of bilirubin and albumin in different brain regions 
in young adult rats during short term (1 h) hyperbilirubinemia, and concomitant 
administration of either a displacing agent (sulfisoxazole), or hypercarbia, or 
hyperosmolarity. Brain/serum bilirubin ratios increased by 58 % (sulfisoxazole), 70 % 
(hypercarbia) and 39 % (hyperosmolarity), but there were no significant inter-regional 
differences in brain uptake in any of the study groups (Hansen et al., 1989). Other 
investigators have found that osmotic opening of the BBB in the rat leads to somewhat higher 
bilirubin concentrations in the basal ganglia than other parts of the brain, but the general 
tendency was that bilirubin staining of the brain was more diffuse than that of the typical 
kernicteric staining pattern seen at autopsy of the newborn infant (Levine et al., 1982).
2.4 The blood-brain barrier and membrane transport proteins 
The BBB restricts the access of hydrophilic compounds, and only lipophilic drugs and 
endogenous compounds can enter the brain by passive diffusion (Fricker & Miller, 2004). 
However, many lipophilic substances such as bilirubin exhibit an unexpectedly low 
concentration in the brain, suggesting additional mechanisms operating at the BBB (Schinkel 
& Jonker, 2003;Tamai & Tsuji, 2000). Many of these compounds are substrates for phospho-
glycoprotein (P-gp), a membrane transport protein that regulates the entry and efflux of 
substrates across cell membranes in many tissues (Lin & Yamazaki, 2003;Schinkel & Jonker, 
2003).
P-gp is a member of the ATP-binding family of membrane transporters. Three 
isoforms of this protein have been identified in rodents (mdr1a, mdr1b and mdr2) and two 
isoforms have been identified in humans (mdr1 and mdr2) (Fricker & Miller, 2004). Studies 
on mdr1a and mdr1a/1b knockout mice suggest that the brain is more sensitive to the changes 
in P-gp function than other tissues (Schinkel et al., 1995). In the brain P-gp exerts its function 
in the capillary vessels by pumping back the substrate upon entry at the luminal membrane 
(facing the blood stream) (Beaulieu et al., 1997;Higgins & Gottesman, 1992;Tamai & Tsuji, 
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2000), and in astrocytes (Gennuso et al., 2004;Pardridge, 1998). Pharmacological inhibition 
of P-gp has been used in, for example, cancer treatment to enhance the influx of anti cancer 
drugs into cancer cells (Bellamy et al., 1988;Slater et al., 1986). Unconjugated bilirubin has 
been shown to be a substrate for P-gp (Jette et al., 1995), raising the question as to whether 
drug-induced inhibition of P-gp may be a mechanism of clinical relevance for bilirubin 
kinetics at the BBB in the newborn infant. In addition to P-gp, transport membrane proteins 
expressed at the BBB also include the multi drug resistance-associated protein (MRP) and the 
organic anion transport proteins (OATp) (Bart et al., 2000;Fricker & Miller, 2004). Bilirubin 
may serve as a substrate for both MRP (Falcao et al., 2007), and OATp (Cui et al., 2001). 
Figure 2. Schematic drawing of P-gp demonstrating two homologous halves with six trans-
membrane regions and a nucleotide binding domain each connected with a linker region 
(shown by courtesy of Gustav Lehne).
2.5 Bilirubin interaction with cell membranes 
Bilirubin diffuses spontaneously through isolated phospholipid bilayers (Hayward et al.,
1986;Zucker et al., 1999). In cultured hepatoblastoma cells bilirubin crosses the cell 
membrane by a mechanism involving spontaneous diffusion (Zucker & Goessling, 2000). It is 
likely that a similar phenomenon exists in neurons, but spontaneous diffusion of bilirubin 
over the neuronal plasma membrane has never been shown. Eriksen et al found that bilirubin 
interaction with phospholipids takes place through three different steps. In the first step the 
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bilirubin dianion attaches reversibly to phospholipids, in the second step the bilirubin-
phospholipid complex  reversibly takes up H+ to form the bilirubin acid-phospholipids 
complex, and in the third step the bilirubin acid aggregates attach to the phospholipids. At pH 
values > 8.2 only the first step is observed, however, at physiologic and acidotic pH values 
the total process is completed within 1 min (Eriksen et al., 1981). These observations were 
supported and further extended in rat synaptosomal plasma membranes (Vazquez et al.,
1988). A study on a human neuroblastoma cell line was not consistent with a simple diffusion 
of bilirubin over the cell membrane, but rather with a multi-step binding mechanism as 
proposed by both Eriksen and Vazquez (Amit et al., 1990). However, rat brain homogenates 
showed elevated intracellular concentrations of bilirubin in the myelin fraction of cellular 
organelles, especially in the mitochondria, ribosomes and cytoplasm after increasing the BBB 
permeability for bilirubin by the induction of hyperosmolarity, strongly suggesting that 
bilirubin does enter the interior of neurons (Hansen et al., 2001).
2.6 Bilirubin elimination from the brain 
Bilirubin is readily removed from the brain. In a rat model where the BBB was opened by 
hyperosmolarity, the half life of bilirubin in the brain has ranged from 1.7 h (Levine et al.,
1985), to 38 min (Hansen, 1996), and was found to be13 min in a model of opening of the 
BBB by hypercarbia (Hansen, 1996). In a different model with intact BBB half life was found 
to be approximately 20 minutes (Hansen & Cashore, 1995). In the two latter studies, 
elimination did not differ substantially within brain regions (Hansen & Cashore, 
1995;Hansen, 1996). Hence, studies of bilirubin clearance from rat brain regions have not 
contributed to our understanding of the phenomenon of the kernicteric staining pattern. The 
mechanism by which bilirubin is eliminated from the brain is not known. Bilirubin may cross 
the BBB either by diffusion or an active transport mechanism back into the circulation 
(Levine et al., 1985) or into the cerebrospinal fluid (Lee & Hsia, 1959). Also, bilirubin may 
be detoxified in the brain by mitochondrial oxidation into non-toxic products (Brodersen & 
Bartels, 1969;Hansen & Allen, 1996a;Hansen, 2000a), however, the clinical relevance of this 
mechanism is not known. Taken together, neither studies on bilirubin entry into the brain, nor 
the elimination of bilirubin from the brain have satisfactorily explained the preference for 
bilirubin accumulation in certain areas of the brain as seen at autopsy of kernicteric infants.
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3. TOXICITY OF BILIRUBIN 
3.1 A case of kernicterus 
In 1907 Beneke gave a detailed description of the clinical features of fatal bilirubin-induced 
encephalopathy in the ”Münchener Medizinische Wochenschrift” (Beneke, 1907). 
“The cases are a pair of twins born prematurely (approximately 6 weeks before term) due to 
an intensely frightening event to the mother. The mother gave birth to healthy twins nine 
years earlier. Later a baby boy was born, but died under similar circumstances as the actual 
twins. Two further pregnancies led to the death of the fetus without detectable cause. The two 
latest-born twins displayed jaundice remarkably early, already after twelve hours. They 
appeared otherwise healthy. Twenty hours after birth, the first-born twin developed light 
seizures (jerking of the extremities); 36 h post partum the doctor observed tonic seizures of 
the extremities and the trunk. Both children drank without difficulties from the spoon until 
shortly before their death. The first-born died at the age of 48 h; the younger with similar 
symptoms 6 h later”.   
In the autopsy description of the first twin Beneke wrote: “Generally the brain is 
only faintly icteric, the cortex no stronger than the medulla. On the other hand, periventricular 
tissues such as the ependymym, the telae and the plexus choroideus appear clear yellowish. 
The thalami are not obviously stained, while the dentate nuclei are somewhat stronger yellow. 
The nuclei of the horn of ammon and the luys bodies on both sides are intensely yellow and 
are sharply distinct from the surroundings. The cortex of the cerebellum is in part stronger 
yellow than the cortex of the cerebrum … . The strongest colouring is found in the nuclei of 
medulla oblongata, especially the nuclei of the trigeminal and acoustic nerves in their whole 
length….” and further “..the peculiar localisation in certain nuclei suggests a specific 
vulnerability to bilirubin for these regions of the brain”.
These fatal cases of bilirubin encephalopathy were most likely due to Rh 
immunization leading to excessive intravascular hemolysis and increase in serum bilirubin 
levels after birth. Prematurity may also have increased the risk of kernicterus.
3.2 Clinical features in bilirubin encephalopathy  
Acute bilirubin encephalopathy, as described above, does not invariably lead to death, but 
may cause persistent neurological disabilities in survivors. The sequel of kernicterus reflects 
the regional distribution of neuronal injury which is most prominent in the basal ganglia, and 
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in the cochlear and oculomotor nuclei. Clinical features include extrapyramidal movement 
disorders like dystonia and athethosis, gaze palsies, and dental dysplasia of baby teeth 
(Maisels, 1999;Volpe, 2003). Auditory abnormalities, which are both central and peripheral 
in origin, are practically invariably present, and may sometimes be the only apparent sequel 
(Johnson et al., 2002). Severe involvement of cerebral cortical neurons is uncommon in 
kernicterus, but several investigators report intellectual deficits, although rarely in the 
mentally retarded range (Day & Haines, 1954;Nilsen et al., 1984;Ozmert et al., 1996).
3.3 Subtle bilirubin encephalopathy in healthy term infants 
Several investigations indicate that moderate degrees of hyperbilirubinemia may be 
associated with an increase in minor neurological dysfunction. In the Collaborative perinatal 
project where more than 41 000 singletons were enrolled, minor motor abnormalities 
increased in a stepwise fashion from 14.9 % in those with TSB levels  171 μmol/L to 22.4 % 
in those with TSB levels  342 μmol/L at the age of 7 years (Newman & Klebanoff, 1993). 
Grimmer et al found that non-hemolytic, apparently healthy term infants with TSB levels in 
excess of 342 μmol/L scored worse on a choreiform dyskinesia scale than controls (TSB 
205 μmol/L) at four years of age (Grimmer et al., 1999). In another study of infants with TSB 
levels of 233 - 444 μmol/L hypotonia or mild abnormalities in muscle tone-regulation in 
combination with significant postural and reflex dysfunction was found in 50 % (versus 10 % 
in the control group) at 12 months of age (Soorani-Lunsing et al., 2001). The sample sizes of 
the two later studies were small, and the clinical importance of theses findings is uncertain 
(Bhutani, 2001;Hintz et al., 2001;Maisels & Newman, 2001). A recent, better designed study 
including 140 newborns with TSB levels exceeding 428 ȝM/L found no differences in the 
proportion of abnormal neurological findings or behavioural problems compared to a matched 
control group at the age of five years (Newman et al., 2006). 
3.4 Reversibility of impaired neuronal function in infants with hyperbilirubinemia  
The risk of prominent neurological abnormalities may correlate not only with the degree of 
hyperbilirubinemia, but also with its duration (Devries et al., 1985;Ozmert et al., 1996). 
Clinical observations suggest that hyperbilirubinemia in infants may alter neonatal behaviour 
and responsiveness, but that these behavioural alterations normalize when hyperbilirubinemia 
subsides (Paludetto et al., 2002). Disturbances in brain auditory evoked potential (BAEP)  in 
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severely hyperbilirubinemic newborns are promptly improved after exchange transfusions 
(Nwaesei et al., 1984), and with modulation of pCO2 in primates (Wennberg et al., 1993). A 
similar phenomenon has been demonstrated in a Gunn rat model of bilirubin encephalopathy 
(Shapiro, 1988;Shapiro, 1993). These phenomena are believed not necessarily to be 
associated with brain damage. However, changes in BAEP may also indicate damage in the 
auditory brainstem (Conlee & Shapiro, 1991;Shapiro & Conlee, 1991). 
3.5 The neuropathology of kernicterus 
The patterns by which yellow staining of the brain occur in the presence of  elevated levels of 
bilirubin, have been summarized by Mamdouha Ahdab-Barmada and include, 1) diffuse 
yellow staining of areas that lack blood brain barrier, including leptomeninges, ependyma, 
choroid plexuses and cerebrospinal fluid, 2) diffuse yellow staining in areas where blood 
brain barrier integrity has become compromised by conditions like hypoxic ischemic 
encephalopathy (HIE), periventricular leukomalacia, ischemic cerebral infarcts, or traumatic 
lesions, 3) classical kernicterus (as described by Beneke) with the typical staining of specific 
neuronal groups including the globus pallidus, the subthalamic nuclei, the hippocampus, the 
oculomotor nuclei, the cranial nerve nuclei, and other nuclei in the lower central part of the 
brain (Ahdab-Barmada, 2000). 
Bilirubin-induced neuronal cell death is typically described as necrosis (Ahdab-
Barmada, 2000;Watchko, 2005a). However, neuropathological investigations on bilirubin 
encephalopathy largely predate the recognition of apoptosis. A recent study on severely 
hyperbilirubinemic infants suggested a more prominent role of apoptotic cell death in 
bilirubin-induced injury than in HIE, based on differences in the diffusion weighted magnetic 
resonance imaging (Groenendaal et al., 2004).  In 7 day old hyperbilirubinemic Gunn rats 
subjected to sulfadimethoxine to enhance brain bilirubin, light microscopic investigations 
indicated apoptotic death in addition to necrosis in neurons (McDonald et al., 1998). To date, 
no further investigations have investigated bilirubin-induced apoptosis in vivo. However,
several recent in vitro studies strongly suggest that apoptosis may play a prominent role in 
bilirubin-induced cell death.
3.6 Experimental studies on bilirubin toxicity 
Animal models using disruption of the BBB to induce entry of bilirubin into the brain have 
shown that bilirubin induces a decline in brain energy metabolites (Wennberg et al.,
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1991;Ives et al., 1989). In the above-mentioned study by Groenendal abnormally high lactate 
values could only be demonstrated in the only infant who later developed severe athetoid 
cerebral palsy (Groenendaal et al., 2004). Bilirubin-induced ATP depletion has also been 
demonstrated in cultured neurons (Cowger, 1971). Whether energy depletion is due to direct 
effects of bilirubin on mitochondrial oxidative phosphorylation (Day, 1954) has later been 
questioned (Diamond & Schmid, 1967;Katoh et al., 1975).
Karp reviewed a number of in vitro studies that predominantly showed 
inhibitory effects of bilirubin on 28 different enzymes, grouped into respiratory and oxidative 
phosphorylation, carbohydrate metabolism, tricarboxylic acid cycle metabolism, amino acid 
and protein metabolism, and lipid metabolism (Karp, 1979). Reversible phosphorylation and 
de-phosphorylation of proteins is a key mechanism for regulation of cellular functions 
(Walaas & Greengard, 1991). Inhibition of protein phosphorylation by bilirubin has been 
shown in newborn rabbits in vivo (Morphis et al., 1982), and in vitro in the synaptic vesicle 
associated protein synapsin I in isolated nerve terminals (Hansen et al., 1988), and in cell free 
systems (Hansen et al., 1996;Sano et al., 1985). In apparent contradiction to these studies, 
bilirubin induced hyper-phosphorylation of MAP kinases in cerebellar granule neurons. These 
MAP kinases are supposed to play a role in bilirubin-mediated apoptosis (Lin et al., 2003).
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4. NECROSIS, APOPTOSIS AND EXCITOTOXICITY 
4.1 Definitions and concepts
The classical concept of toxic action on cell homeostasis is the one of a dose-dependent 
progression from reversible adaptive changes in cellular metabolism to a major and 
irreversible collapse of cellular homeostasis resulting in disintegration of the cellular 
membrane and cell death seen as necrosis. Over the last 30 years it has become evident that 
cells of multi-cellular organisms have the ability to activate an internal cell death program 
which has been labelled programmed cell death. Programmed cell death may be identified 
primarily due to cellular morphological changes referred to as apoptosis. In this thesis both 
the phenomenon of programmed cell death and its morphological consequences will be 
referred to as apoptosis. The term excitotoxicity refers to the ability of glutamate and 
structurally related amino acids to induce cellular damage mediated by glutamate sensitive 
receptors on the cell surface (Choi, 1992). 
After the recognition of apoptosis, Wyllie put forward two postulates concerning 
non-necrotic cell death; that apoptosis is induced by insults of lesser amplitude than those 
causing necrosis in the same cell, and that apoptosis is more prone to occur in cells primed for 
apoptosis (Wyllie, 1987). The two classical types of cell demise can occur simultaneously in 
tissues or cell cultures exposed to the same stimulus, and the magnitude of the same insult 
decides the prevalence of different forms of cell death (Bonfoco et al., 1995;Nicotera et al.,
1999). After a given insult the metabolic state of the cell is of vital importance for the cell’s 
decision to survive or undergo apoptotic or necrotic cell death (Ankarcrona et al.,
1995;Nicotera & Leist, 1997). Typically, necrotic cell death is an early event in a 
subpopulation of cells, while apoptosis is a slower process (Ankarcrona et al., 1995;Castoldi 
et al., 2000;Ding et al., 2000).
4.2 Caspase-dependent apoptosis 
Various apoptotic stimuli like activation of receptors on the cell surface, serum deprivation, 
ionizing radiation, or toxic stimuli, may trigger the activation of apoptosis (Widlak & 
Garrard, 2005). The core biochemical apoptotic pathway is executed by a family of cysteine 
proteases, so-called caspases, which are activated during the progress of the apoptotic 
process. They are synthesized as inactive pro-enzymes which are activated by proteolytic 
cleavage (for reviews see Degterev et al., 2003;Earnshaw et al., 1999). To date at least 
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fourteen caspases have been identified, of which at least seven contribute to cell death (Chang 
& Yang, 2000). Caspases execute their role as cell killers by carrying out the limited cleavage 
of over 100 cellular proteins at the site of key aspartic residues leading to the orderly 
disassembly of the cell and the morphological features of apoptosis (Earnshaw et al.,
1999;Ryan & Salvesen, 2003). The execution of caspase-mediated apoptosis is the result of a 
cascade of events resulting in the activation of the executioner caspases -3, -6, or -7, where 
caspase-3 has been identified as a major executioner caspase (Nicholson et al., 1995;Racke et
al., 2002). Caspase-mediated apoptosis is an energy requiring process, and a sufficient ATP 
concentration must be sustained throughout the apoptotic execution for the final 
morphological and biochemical features to occur (Leist & Nicotera, 1997;Nicotera et al.,
2000).
The caspase-dependent apoptotic signalling pathways can be divided into two 
categories; cell surface sensor mediated (extrinsic) and intracellular sensor mediated (intrinsic 
or mitochondrial). In the intrinsic pathway an apoptotic insult induces permeabilization of the 
mitochondrial membrane resulting in the release of cytochrome c from the mitochondria to 
the cytosol (Earnshaw et al., 1999;Zou et al., 1997). Cytochrome c combines with the 
protease activating factor (Apaf-1), procaspase-9, and ATP to form the apoptosome complex, 
which activates caspase-9 (Degterev et al., 2003;Polster & Fiskum, 2004). The activation of 
caspase-9 leads to the proteolytic activation of the effector caspases caspase-3 and (to a lesser 
extent) caspase-7 (Degterev et al., 2003;Polster & Fiskum, 2004). Cytochrome c-release and 
apoptosome formation is regulated through a complex and incompletely understood interplay 
of pro-apoptotic and anti-apoptotic factors, many of which belong to the Bcl-2 family of 
proteins (Degterev et al., 2003;Zamzami et al., 1998). Activation of PARP, a cell defence 
mechanism during apoptosis, is an energy requiring process leading to a decrease in 
intracellular ATP levels. Caspase-3 cleaves PARP terminating PARP activity, which may be 
viewed as an attempt to preserve sufficient energy to undergo apoptosis (Degterev et al.,
2003).
In the extrinsic pathway extra-cellular ligands bind to cell death receptors, many 
of which belong to the tumor necrosis factor receptor (TNFR) super family of receptors. 
These receptors have a common intracellular sequence known as the death domain which 
through binding of the ligand (e. g. TNF-Į, or FAS) promotes recruitment of adapter proteins 
that result in the formation of a death inducing signalling complex (DISC). Recruitment of 
procaspase-8 to this complex promotes its transition to the active form. Executioner caspases 
such as caspase-3 may be activated by caspase-8 in a direct fashion, or, for more efficient 
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killing of cells, this process may be amplified at the mitochondria by a mechanism involving 
pro-apoptotic members of the Bcl-2 family (Degterev et al., 2003;Polster & Fiskum, 2004).  
Both intrinsic and extrinsic apoptotic pathways are regulated by the interplay of 
multiple signalling pathways, such as the mitogen activated protein kinases (MAPK) which 
are activated by various environmental stresses. They mediate their function by 
phosphorylation of different kinase systems such as the jnk and p38 signalling pathways. 
These may either amplify the stress signal leading to enhanced apoptosis or reduce apoptosis 
by the activation of apoptosis inhibitors (for review see Mehta et al., 2006) 
4.3 Caspase inhibitors and caspase-independent apoptosis 
The action of caspases may be blocked by endogenous substances such as free oxygen 
radicals (Hampton & Orrenius, 1998), by the influence of exogenous caspase inhibitors such 
zVAD.FMK (Volbracht et al., 2001), or by the lack of intracellular ATP (Leist et al.,
1997;Nicotera et al., 1998). Inhibition of the caspase machinery does not necessarily prevent 
cell death indefinitely, and it seems that alternative cell death pathways are activated as a 
result of the inhibition of caspases (Stefanis, 2005;Volbracht et al., 2001). This has revealed 
the existence of alternative cell death pathways which are independent of caspases (Lorenzo 
& Susin, 2004;Stefanis, 2005).
Apoptosis-inducing factor (AIF) is a pro-apoptotic protein which may have a 
key role in neuronal injury. Upon mitochondrial permeabilization, AIF translocates from its 
normal location at the mitochondrial inter-membrane space to the nucleus, inducing 
chromatin condensation and DNA degradation. In most models AIF-mediated apoptosis is 
independent of caspases (Cheung et al., 2005;Wang et al., 2004). Endonuclease G is another 
protein that may translocate to the nucleus to induce caspase-independent DNA degradation 
(Lorenzo et al., 1999;Lorenzo & Susin, 2004). Thus, neurons can die by the involvement of 
caspase-dependent mechanisms, caspase-independent mechanisms or both, depending on the 
insult. In general the mitochondria are crucial for both caspase-mediated and caspase-
independent pathways (Li et al., 2005;Wang et al., 2004). The mitochondrion may be seen as 
a weapons store where a cocktail of caspase-dependent and -independent pro-apoptotic 
proteins are dormant until a death process is triggered (Lorenzo & Susin, 2004). AIF and 
caspases may cooperate in the cell death cascade, and their individual contribution may 
depend on the specific apoptosis-inducing stimulus and the cell type (Cande et al., 2002) . 
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Figure 3.  Release of caspase-dependent and caspase-independent pro-apoptotic factors from 
the mitochondria. Diverse toxic influences induce mitochondrial membrane permeabilization 
to cause the release of apoptotic molecules from the mitochondria. The release of pro-
apoptotic factors such as Smac/Diablo may facilitate caspase activation through their 
inhibitory function on inhibitory apoptotic proteins (IAPs). Activated caspase-3 is required to 
convert iCAD into its active form, CAD (caspase-activated DNase), which enters the nucleus 
inducing internucleosomal DNA fragmentation and advanced chromatin condensation 
typically appearing as nuclear fragmentation. In response to apoptotic stimuli mitochondria 
may also release caspase-independent cell death effectors such as apoptosis inducing factor 
(AIF) or Endonuclease G. These factors translocate to the nucleus inducing high molecular 
weight (HMW) DNA fragmentation and less advanced chromatin condensation appearing as 
nuclear pycnosis (see text) (derived from Cregan et al., 2004). 
4.4 Excitotoxicity
The term excitotoxicity refers to the ability of glutamate and structurally related amino acids 
to damage neurons (for review see Choi, 1992). Glutamate is the major excitatory 
neurotransmitter in the brain, and glutamate-mediated synaptic transmission is critical for the 
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normal functioning and development of the nervous system (McDonald & Johnston, 1990). 
Glutamate acts on four different families of ionotrophic receptors; the N-methyl-D-aspartate
(NMDA) receptor, the a-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) 
receptor, the kainite receptor, and on metabotrophic receptors linked to G-proteins (Choi, 
1992). Over-activation of the NMDA receptor by glutamate accounts for the majority of 
glutamate excitotoxicity, with a lesser role for non-NMDA receptor activation (Choi, 1992). 
Excessive extra-cellular glutamate or increased sensitivity of the NMDA receptor to 
glutamate may induce increased Ca2+ influx and release of Ca2+ from intracellular stores 
leading to the activation of Ca2+-dependent enzymes and mitochondrial production of reactive 
oxygen species which may initiate cell death (Choi, 1992;Leist & Nicotera, 1998).
Excitotoxic cell death has formerly been reported to be mainly necrotic (Leist & 
Nicotera, 1998). More recent evidence has shown that cells which are exposed to excitotoxic 
injury, but are able to maintain ATP production for some time, die from apoptosis, while 
neurons which do not maintain sufficient energy production undergo necrosis (Ankarcrona et 
al., 1995;Leist & Nicotera, 1998). While some studies have found that relatively low 
concentrations of glutamate may activate caspase-3 (Du et al., 1997;Zhao et al., 2000), it is 
now generally held that glutamate-induced apoptosis is independent of caspase activation in 
most in vitro model systems (Cheung et al., 2005;Wang H et al., 2004). The exact 
mechanisms by which excitotoxic injury induces caspase-independent apoptosis is 
incompletely understood, however, both calcium-dependent proteases called calpains 
(Stefanis, 2005;Polster et al., 2005) and AIF are reported to be involved (Wang et al., 2004). 
 Taken together, excitotoxic neuronal death may involve both necrotic and 
apoptotic cell death dependent on the magnitude of the insult and the metabolic state of the 
neuron. In most model systems of cell death excitotoxic cell death is independent of caspase 
activity in vitro.
4.5 Detection of apoptosis 
There is no definition for either necrosis or apoptosis that precisely distinguishes between the 
different forms of cell death. It is also a matter of debate whether apoptosis and necrosis 
represent discrete modes of cell or death or rather a continuum, where classical apoptosis and 
necrosis represent two extremes (Northington et al., 2005;Raffray & Cohen, 1997). 
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Table 1. Comparison of the features of apoptosis and necrosis (adapted from Allen et al.,
1997).
In the cytoplasm activated caspases cause breakdown of the cytoskeleton, loss of 
contact with neighbouring cells, cell shrinkage, and blebbing of the cytoplasm followed by 
disintegration into apoptotic bodies. In contrast to necrosis, the plasma membrane and 
cytoplasmic organelles of the apoptotic cell remain intact. In vivo the apoptotic cell is readily 
phagocytized by the organism, however, due to the absence of phagocytosis in neuronal 
cultures, the cell membrane of apoptotic cells also disintegrate eventually; so called 
secondary necrosis (from Foster JR, 2000). Parameters which denote membrane integrity, 
such as LDH- release to the supernatant and dye exclusion tests such as trypan blue, 
propidium iodide, or ethidium homodimer are more reliable in the detection of necrosis than 
apoptosis.
Two different apoptotic pathways are thought to mediate DNA fragmentation 
and condensation during apoptosis. In one pathway DNA is cleaved into high molecular 
weight (HMW) fragments of 50-300 kb. This pathway is accompanied by chromatin 
condensation at the nuclear periphery and, at least in some paradigms of cell death, pycnotic 
nuclear condensation. This pathway does not require activation of caspases, and other cell 
   Apoptosis             Necrosis 
Occurence  Scattered, single cells Massive tissue injury 
Cytoplasm  Shrinkage: condensed and dehydrated;  Swelling: Endoplasmatic reticulum,  
 normal organelles; later fragments and mitochondria  
Nucleus  Chromatin condenses into Ill defined, randomly dispersed,  
 masses adjacent to the nuclear smaller chromatin masses; later  
 envelope, later pycnosis or fragmentation lysed 
Plasma and 
nuclear  Intense blebbing; apoptotic bodies  Membrane injury/lysis, leakage of 
membrane  containing normal cytoplasmic organelles  intracellular contents 
 and nuclear chromatin   
Tissue response  No inflammation; phagocytosis of  Inflammation 
  apoptotic bodies   
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death effectors such as AIF or Endonuclease G have been shown to activate this pathway 
(Lorenzo et al., 1999;Lorenzo & Susin, 2004). The other pathway is caspase-dependent and 
involves activated caspase-3, which in turn converts iCAD into its active form CAD (caspase-
activated DNase). CAD enters the nucleus inducing internucleosomal DNA fragmentation 
and advanced chromatin condensation, often appearing as nuclear fragmentation (Susin et al.,
2000;Walker et al., 1999).
It is now generally held that only HMW DNA fragmentation is essential for 
apoptosis (Susin et al., 2000;Walker et al., 1999). This implies that the final morphological 
and biochemical features of caspase-dependent apoptosis such as oligonucleosomal DNA 
fragmentation (the DNA ladder) and morphological nuclear fragmentation, may not always be 
present in apoptotic cells. In cerebellar granule cells glutamate induces typical signs of 
apoptosis such as pycnotic nuclear chromatin condensation and HMW DNA degradation, 
while exposure to a different apoptotic stimulus such as staurosporine induces a different 
apoptotic phenotype with nuclear fragmentation and typical DNA laddering (Nicotera et al.,
1999).                                         
With emphasis on the in vitro situation, detection of  apoptosis may include; 1) 
typical apoptotic morphological hallmarks of the cell body, like condensation and 
fragmentation which are detectable by light microscopy or electron microscopy, 2) nuclear 
morphological hallmarks such as nuclear condensation and fragmentation visible after the 
staining with dyes such as Hoechst 33342, 3) direct measurements of the activity of 
executioners of the apoptotic process such as activated caspases, members of the Bcl-2 family 
or cytochrome c, 4) biochemical hallmarks, occurring as a result of the apoptotic process, 
such as PARP cleavage, oligonucleosomal DNA fragmentation, and systems that permit the 
localisation of DNA breaks, like in situ end labelling (ISEL) or the terminal deoxynucleotidyl 
transferase-mediated dUTP nick end labelling (TUNEL), and 5) the ability of caspase 
inhibitors or other inhibitors of the apoptotic process (PARP inhibitors, AIF inhibitors) to 
prevent apoptotic cell death (or morphologies) (Foster JR, 2000;Joashi et al., 1999).
4.6 Bilirubin and apoptosis  
While evidence of apoptosis is scarce in newborn infants and intact animals exposed to 
bilirubin, in vitro studies strongly suggest that apoptosis is a prominent feature in bilirubin-
mediated neuronal injury. Evidence includes studies on primary cultures of cortical neurons 
from fetal rodents (Grojean et al., 2000;Grojean et al., 2001;Rodrigues et al., 2000;Rodrigues 
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et al., 2002a;Rodrigues et al., 2002b;Rodrigues et al., 2002c;Silva et al., 2001b;Silva et al.,
2002), on primary cultures of astrocytes from fetal rodents (Rodrigues et al., 2000;Rodrigues 
et al., 2002b;Rodrigues et al., 2002c;Silva et al., 2001b;Silva et al., 2002), on murine 
hepatoma cells (Seubert et al., 2002), on cultured bovine endothelial cells (Akin et al., 2002), 
and on colon cancer cells (Keshavan et al., 2004). Evidence of apoptosis has come forth 
through the use of apoptotic markers such as characteristic nuclear morphological changes 
(Grojean et al., 2000;Grojean et al., 2001;Rodrigues et al., 2000;Rodrigues et al.,
2002a;Rodrigues et al., 2002b;Rodrigues et al., 2002c;Seubert et al., 2002;Silva et al.,
2001b;Keshavan et al., 2004), mitochondrial cytochrome c release in intact cells (Rodrigues 
et al., 2002a;Seubert et al., 2002;Keshavan et al., 2004), or from isolated mitochondria after 
direct exposure to bilirubin (Rodrigues et al., 2000;Rodrigues et al., 2002c), caspase-3 
activation (Rodrigues et al., 2002a;Seubert et al., 2002;Keshavan et al., 2004), caspase-8 
activation (Seubert et al., 2002;Keshavan et al., 2004), TUNEL-staining (Silva et al.,
2001b;Silva et al., 2002), oligonucleosomal DNA fragmentation (Akin et al., 2002), and 
PARP cleavage (Akin et al., 2002;Rodrigues et al., 2002a).
 Recent investigations have shown that bilirubin causes the release of 
inflammatory mediators such as IL-6 and TNF-Į in cultured astrocytes (Fernandes et al.,
2004;Fernandes et al., 2006). MAP kinases are involved in the regulation of this release, and
treatment with specific inhibitors of MAP kinases such as p38, JNK and ERK prevented the 
release of these cytokines and subsequent apoptosis (Fernandes et al., 2007). 
 4.7 Bilirubin and excitotoxicity 
Several studies both in vivo and in vitro suggest that bilirubin may exert its toxic effects at 
least in part over the ionotropic NMDA receptor. In piglets bilirubin increased the affinity of 
the NMDA receptor for MK-801 in the brain, possibly due to conformational changes of the 
ion channel complex (Hoffman et al., 1996). In the brain glutamate uptake by astrocytes 
normally prevents excitotoxic glutamate elevations in the extra cellular space  Exposure of 
nerve cells to bilirubin enhances the extra cellular concentration of glutamate either by 
decreased uptake (Silva et al., 1999;Wennberg et al., 1994), or by enhanced release 
(Fernandes et al., 2004).
Gunn rats with substantial hyperbilirubinemia were consistently more 
susceptible to brain injury after injections of NMDA into the brain than non-jaundiced 
controls. Concurrent treatment with the NMDA receptor blocker MK-801 reduced cell death 
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(McDonald et al., 1998). Two in vitro studies by Grojean et al on cultured cortical neurons 
from rat pups showed that apoptosis induced by a low bilirubin concentration (0.5 ȝM) alone 
or concurrent with hypoxia was completely abrogated by treatment with MK-801 (Grojean et 
al., 2000;Grojean et al., 2001). Their results indicated that bilirubin-mediated excitotoxicity 
was executed predominantly by caspase-dependent pathways (Grojean et al., 2000).
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5.1 SUMMARY OF BACKGROUND FOR THE THESIS 
To date, no unifying, single mechanism of bilirubin toxicity has been demonstrated. The 
mechanisms operating at the BBB to regulate bilirubin entry into the brain are incompletely 
understood. Also, neither studies on bilirubin entry into the brain, nor the elimination of 
bilirubin from the brain have satisfactorily explained the preference for bilirubin 
accumulation in certain areas of the brain as seen at autopsy of kernicteric infants. 
The wide variety of deleterious effects caused by bilirubin may suggest that 
bilirubin excerts its toxic effects on multiple sites of cellular metabolism. While apoptotic and 
excitotoxic mechanisms have been convincingly demonstrated in bilirubin-mediated toxicity, 
the relative impact of excitotoxic pathways and their relation to caspase-mediated and non 
caspase-mediated cell death needs further investigation. In a recent paper Shapiro stated that 
“the different patterns of expression of bilirubin- induced injury may relate to 1) the amount 
and duration of exposure to bilirubin, 2) variation in susceptibility of the nervous system, 3) 
the relative amount of necrosis vs. apoptosis produced, and 4) whether surviving neurons 
become functionally normal or are more susceptible to other stressors either at the time of 
hyperbilirubinemia or afterwards” (Shapiro, 2005). 
Recent evidence from studies on newborn rodents suggests that the immature 
brain may be more susceptible to both excitotoxicity (McDonald & Johnston, 1990) 
(McDonald et al., 1998) and apoptotic cell death (Hu et al., 2000;Lesuisse & Martin, 2002) 
(Zhu et al., 2005) than the adult brain. These findings should encourage further studies of the 
role of excitotoxicity and apoptosis in bilirubin-mediated injury in newborns. Also, no prior 
investigations have been undertaken on neuronal cells of human origin.  
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5. 2 AIMS OF THE THESIS 
Our understanding of the mechanisms of bilirubin entry into the brain and the mechanisms of 
neuronal injury is inadequate. Bilirubin is a substrate for the membrane transport protein P-gp 
which has been attributed an important role in the regulation of entry into and expulsion of 
compounds from the brain. In the first study (paper I) we hypothesized 1) that treatment with 
drugs known to inhibit P-gp function would modify bilirubin entry into the brain of young 
adult rats and 2) that such drugs might affect the regional distribution pattern of bilirubin in 
the brain.
In the remaining studies (papers II, III and IV) we used human NT2-N neurons 
to determine the modes of cell death and its temporal evolution after exposure to various 
concentrations of bilirubin in a model of continuous exposure to bilirubin for up to 96 h and 
in a model of short term exposure (6 h) to bilirubin. To elucidate the roles of caspases and 
excitotoxicity, we investigated the effects of treatments with two different caspase inhibitors 
and/or an NMDA receptor antagonist in both continuous and short term exposure (paper III 
and IV). In additional experiments we evaluated the added impact of serum deprivation in our 
model of long term bilirubin exposure (96 h) (paper IV).  
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6. SUMMARY OF RESULTS 
Paper I
We hypothesized that pre-treatment with drugs known to inhibit P-gp function administered 
in clinically relevant doses in the newborn would alter the uptake of bilirubin in the brain of 
32-36 days old Spraque Dawley rats. In the first arm of the study, the animals received pre-
treatment with an iv infusion of the respective drug (or saline in controls) 10 min before an iv 
bolus of 50 mg/kg bilirubin given over 5 min. The animals were sacrificed 15 min after the 
initiation of the bilirubin infusion and brain bilirubin was determined by acid chloroform 
extraction. Due to significant differences in serum bilirubin values (rats receiving verapamil) 
a brain-to-serum bilirubin ratio was calculated. Control animals (n = 12) had a brain/serum 
bilirubin ratio of 3.2 ± 0.8 (x 10-3). Rats receiving pre-treatment all showed enhanced 
brain/serum bilirubin ratios (all x 10-3); propanolol 4.7 ± 1.6 (n = 7), ceftriaxone 7.6 ± 2.5 (n 
= 7), rifampin 5.3 ± 1.4 (n = 6), verapamil 4.6 ± 1.5 (n = 11), and erythromycin 4.0 ± 0.7 (n = 
6). The increase in brain-to-serum bilirubin ratios was significant for all treatments (p < 0.05, 
two tailed t-test with Welch correction) except for erythromycin. Ceftriaxone is also a 
displacer of bilirubin at the albumin binding site, which may have contributed to the increased 
brain bilirubin in animals treated with this drug. 
In the second study arm we hypothesized that pre-treatment with two of the 
drugs shown to increase total brain bilirubin, ceftriaxone and rifampin, would alter the 
regional distribution of bilirubin in the brain. With the exception that radioactive bilirubin 
was used (20 μCi, for each animal), the procedure was identical to the one described above. 
Analysis of seven different brain regions (cortex, hippocampus, striatum, hypothalamus, 
midbrain, cerebellum and medulla) by scintillation counting showed that the concentrations 
differed significantly among brain regions in all three study groups (p < 0.001). The pattern of 
distribution was similar in controls and ceftriaxone-treated rats in that both groups had 
significantly higher bilirubin concentrations in the cerebellum. In the rifampin-treated rats the 
distribution pattern was different in that the bilirubin concentration was significantly lower in 
the cerebral cortex than in the cerebellum and the medulla. However, these changes in 
distribution were not in accordance with a kernicteric staining pattern.  
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Paper II 
NT2-N neurons were exposed to different concentrations of bilirubin and bovine serum 
albumin (BSA) at molar ratios (MR) of 1.5 and 3. Bilirubin induced a dose dependent (0.66 - 
250 ȝM/L bilirubin) decrease in neuronal viability as measured with 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazoliumbromide (MTT) assays for both MRs at 24 h. Bilirubin/BSA 
MR 3 was significantly more potent than MR 1.5 in reducing neuronal viability (p < 0.0001). 
All further experiments were undertaken with bilirubin/BSA MR 1.5, and multiple, 
independent measures of cell damage were used to evaluate neuronal injury after 6, 24, and 
48 hours.
2 and 5 μM bilirubin caused necrotic cell death in a small subpopulation within 
24 h. 10 and 25 μM caused substantial early necrotic cell death at 6 h, further increasing up to 
24 h, but not thereafter. High concentrations of bilirubin (100 μM) caused almost complete 
necrotic cell death at 6 h accompanied by severe early impairment of MTT reduction. 
Apoptosis was the predominant mode of cell death after exposure to bilirubin concentrations 
 10 μM. Apoptosis was associated with maintained neuronal metabolism as indicated by 
MTT reduction. We defined apoptosis basically according to morphological criteria to consist 
of nuclear condensation or nuclear fragmentation. These two entities displayed differences in 
temporal evolution, as nuclear condensation appeared earlier and did not increase beyond 24 
h (a maximum value of 25 ± 8 % in neurons exposed to 25 μM), while nuclear fragmentation 
first occurred at 24 h and continued to increase up to 48 h (a maximum value of 37 ± 11 % in 
neurons exposed to 10 μM). PARP cleavage and oligonucleosomal DNA fragmentation 
(DNA laddering) was found in cells treated with 5 μM bilirubin, but not with higher bilirubin 
concentrations. 2 μM staurosporine (used as a positive control for apoptosis) caused 
predominantly apoptotic cell death with a predominance of fragmented nuclei (61 % 
fragmentation at 48 h) and prominent PARP cleavage and DNA laddering.
To conclude, bilirubin induced both apoptosis and necrosis in neurons. 
Apoptosis was the predominant mode of cell death after exposure to low and moderate 
bilirubin concentrations.
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Paper  III 
To investigate the role of caspases and excitotoxicity in bilirubin-induced cell death, we 
exposed NT2-N neurons to 5 μM bilirubin (a concentration known to induce apoptosis) or 2 
μM staurosporine (positive apoptosis control), and investigated the effects of treatments with 
the specific caspase-3 inhibitor, zDEVD.FMK (20 and 100 μM), or the general caspase 
inhibitor, zVAD.FMK (20 and 100 μM), and/or the NMDA receptor antagonist MK-801 (10 
μM) during a 24 h or 48 h exposure.
 Bilirubin increased caspase-3 activity 2.3-fold after six hours. Despite this, 
treatment with zDEVD.FMK did not significantly reduce cell death. Treatment with the 
general caspase inhibitor zVAD.FMK significantly enhanced neuronal survival, however, this 
effect was not reflected in the MTT assays. General caspase inhibition reduced nuclear 
fragmentation (at morphological evaluation) and oligonuclesomal DNA fragmentation (the 
DNA ladder) more potently than caspase-3 inhibition. Caspase inhibition did not affect 
necrotic cell death (condensed nuclei with disrupted membrane). In cells exposed to 
staurosporine caspase-3 activity increased 7.8-fold after a six hour exposure, and both caspase 
inhibitors highly significantly reduced neuronal death at 24 and 48 h. Caspase inhibition 
markedly changed the pattern of nuclear morphology and DNA fragmentation in cells 
exposed to staurosporine in a similar way as seen in bilirubin-mediated injury.  
 Treatment with MK-801 reduced bilirubin-induced cell death after 48 h (40 ± 
22 % vs 21 ± 17 % undamaged nuclei, p = 0.03), but significant protective effects were not 
found in the MTT assays. Treatment with MK-801 reduced apoptotic nuclear condensation, 
but did not influence the number of cells displaying nuclear fragmentation. Treatment with 
MK-801 had no effect on the proportion of necrotic nuclei. Co-treatment with MK-801 and 
zVAD.FMK (100 ȝM) reduced apoptotic morphologies after 24 h (88 ± 6 % vs 58 ± 16 % 
undamaged nuclei, p = 0.001) and 48 h (59 ± 21 % vs 21 ± 17 % undamaged nuclei, p = 
0.0002). MTT assays showed similar effects of combined treatment. Combined treatment also 
showed significant effects versus treatment with MK-801 alone after 24 h (88 ± 6 % versus 
71 ± 17 % undamaged nuclei, p < 0.05), but was not significant after 48 h (p = 0.051). Taken 
together, bilirubin induces apoptosis in human NT2-N neurons by excitotoxic mechanisms 
and by caspase-mediated pathways. Apparently these pathways are, at least in part, distinct in 
this model. Concomitant inhibition of both these pathways synergistically prevented cell 
death.
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Paper IV 
We used human NT2-N neurons to investigate delayed effects of short-term exposure to 
unconjugated bilirubin (UCB). Cell viability was evaluated with MTT reduction assays and 
nuclear morphology. A 6 h exposure to 1, 5, or 25 μM UCB and serum deprivation 
significantly diminished MTT reduction (74 ± 11%, 67 ± 15%, and 59 ± 6% of control 
values, p = 0.01, 1 vs. 25 μM). 96 h after rescue of neurons with removal of UCB and re-
incubation in the original serum-containing medium, delayed effects were evident as 
recovery (1 μM UCB), intermediate cell death (5 μM UCB), or near complete cell death (25 
μM UCB). In this model, treatment with the specific caspase-3 inhibitor, zDEVD.FMK 
(100 μM), or the pancaspase inhibitor zVAD.FMK (100 μM) did not improve viability in 
rescued neurons exposed to 5 μM UCB. On the other hand, treatment with the NMDA 
receptor antagonist MK-801 (10 μM) enhanced the number of undamaged nuclei versus 
controls (86 ± 14% vs. 50 ± 12%, p = 0.001), but had no impact on MTT reduction. In a 
different model with 102 h neuronal exposure to UCB and serum deprivation, we found an 
additional toxic impact of serum deprivation. Separate experiments suggested that this was a 
result of late caspase-mediated toxicity. The impact of a 6 h serum deprivation alone 
appeared to be modest in rescued neurons. We conclude that UCB-mediated effects are 
reversible in this model. Blockade of excitotoxic mechanisms, but not caspase activity, may 
prevent delayed cell death.
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7. METHODOLOGICAL CONSIDERATIONS 
The methods are stated in “Methods” in the respective papers. The following section is 
concerned with important methodological considerations of particular importance for the 
reliability of the studies. 
7.1 Rat models and membrane transport proteins
The Gunn rat develops hyperbilirubinemia postnatally due to a congenital deficiency in the 
activity of glucuronyl transferase (McDonald et al., 1998), and has been much used in the 
study of bilirubin-induced encephalopathy. The Gunn rat expresses P-gp (Jon Watchko 
personal communication). However, due in part to the high cost of Gunn rats we choose 
Sprague Dawley rats for our experiments. This rat strain also expresses P-gp (King et al.,
2001), and has been much used in the study of bilirubin entry into and elimination from the 
brain (Hansen & Cashore, 1995;Hansen, 1995;Hansen, 1996;Hansen & Allen, 1996b). In 
these rats hyperbilirubinemia is created by injection of solubilized bilirubin. A problem in the 
use of newborn rats for experiments is that iv infusions and adequate blood sampling is 
technically extremely difficult due to their small size. Thus, nearly all studies have used 
young adult animals at the age of approximately five weeks (Hansen & Cashore, 
1995;Hansen, 1995;Hansen, 1996;Hansen & Allen, 1996b). This raises doubt about their 
relevance to the question of bilirubin toxicity in the newborn period. To some extent this may 
be counteracted by the fact that rat brain development continues at least until three months of 
age (Altman, 1969). The ontogeny of membrane transport protein and their functionality in 
newborn rats is, however, not well known.
In the Sprague Dawley rat expression of P-gp has been shown in olfactory 
neurons from embryonic day 14 (KulkarniNarla et al., 1997). In Wistar rats, brain P-gp was 
not detected until postnatal day 7 and adult levels were reached at postnatal day 28, mainly in 
the brain capillary endothelial cells in the cerebellum, the hippocampus and the frontal cortex 
(Matsuoka et al., 1999). In mice, brain P-gp was expressed from embryonic day 16, and adult 
levels were reached by postnatal day 21 (Tsai et al., 2002). This evolution seems to parallel 
the expression of P-gp in the human brain (Tsai et al., 2000). Organic anion transport protein 
(OATp) is expressed in the brain of adult rats both at the BBB and in the choroid plexus (Gao 
et al., 1999;Gao et al., 2000). However, information on the expression and function of OATp 
and MRP in the newborn is, to our knowledge virtually non-existing.
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7.2 NT2-N neurons in the study of perinatal brain injury 
The human teratocarcinoma-derived cell line Ntera2/clone D 1 has the ability to differentiate 
into post-mitotic neurons when treated with retinoic acid (RA) (Pleasure et al., 1992). RA, 
RA-binding proteins and RA receptors are detected in the embryonic brain, and RA is thought 
to play an important role in the differentiation of neurons during development (Horton & 
Maden, 1995;Rossant et al., 1991). According to our protocol Ntera2/clone D 1 cells were 
treated with RA for 4 weeks. At this stage of development, 5 % of the cells are neurons as 
judged by the presence of neuron-specific markers (Pleasure et al., 1992). Neuronal cells 
were then mechanically dislodged from the bottom non-neuronal layer. Thereafter, treatment 
with mitotic inhibitors for another four weeks eliminates almost all the remaining non-
neuronal cells, but has no apparent effect on NT2-N neurons (Pleasure et al., 1992). After two 
weeks of treatment with mitotic inhibitors, 95 % of the cells are differentiated neurons with a 
wide network of processes which can be identified as dendrites and axons (Pleasure et al.,
1992).
In non-differentiated cells (prior to RA-treatment) apoptosis is a rare event. 
However, during RA treatment apoptosis increases three fold (Zigova et al., 2001). 
Glutamate-evoked currents are detected in all cells after 6 weeks (Younkin et al., 1993), and a 
gradual sensitivity to glutamate develops in parallel to the increased expression of NMDA 
receptors (Munir et al., 1995), and non-NMDA receptors (Hardy et al., 1994). At the time of 
the experiments the density of NMDA receptors in the NT2-N neurons is 1/10 of that found 
in mature rat hippocampal membranes, but is similar to that found in human neurons (Munir 
et al., 1996). NT2-N neurons also express functional GABA receptors, predominantly of the 
same subtype as found at early stages in the rat brain (Matsuoka et al., 1997;Neelands et al.,
1998), and functional calcium channels (Neelands et al., 2000). A recent study showed that 
apoptotic functional genes of the extrinsic apoptotic pathways were significantly up-regulated 
after exposure to ethanol in NT2-N neurons (Chen et al., 2005) 
Human NT2-N neurons are not derived from the central nervous system. 
However, upon treatment with RA these cells develop characteristics of neurons which are 
reflected in their morphological appearance, expression of protein markers and receptors and 
the acquired post-mitotic state. There are strong arguments that these cells may function in a 
neuron-like manner. Transplantation of NT2-N cells into the striatum after focal cerebral 
ischemia in rats has been shown to improve motor function (Borlongan et al., 1998). 
Furthermore, in human stroke patients the transplantation of terminally differentiated NT2-N 
neurons survived for 27 months without reverting to a neoplastic state (Nelson et al., 2002). 
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Human NT2-N neurons have proven a useful model in the study of HI cell death (Almaas et
al., 2000;Almaas et al., 2002;Rootwelt et al., 1998) and to elucidate apoptotic mechanisms  
(Cardoso et al., 2004a;Cardoso et al., 2004b;Walker et al., 1999). Caspase-3 activation has 
been shown after exposure to serum deprivation in NT2-N neurons (Walker et al., 1999). 
Furthermore, calpain inhibitors reduced hypoxic injury in this cell line (Almaas et al., 2003). 
No investigations have addressed the role of AIF or endonuclease G in cell death in NT2-N 
neurons.
7.3 Solubility and toxicity of bilirubin in culture medium 
In studies of cultured cells the culture medium is the equivalent of the interstitial fluid of the 
brain. Very little information exists on bilirubin concentrations in the interstitial fluid that 
may be relevant to the induction of bilirubin-mediated injury in vivo. In one study 
concentrations of 5 ȝmol/l bilirubin were found in the cerebrospinal fluid of infants with a 
mean bilirubin concentration of 222 ȝmol/l (Meisel et al., 1981). This value corresponds well 
with the bilirubin concentrations in brain tissue of jaundiced animals (Bratlid, 1990).  As 
stated previously, the solubility of bilirubin has been estimated to be as low as 7 nmol/L in 
aqueous solutions (Brodersen, 1979). Once aggregates are formed, changes in unbound 
bilirubin concentrations occur, giving rise to experimental variability. In aqueous solutions 
the bilirubin molecule aggregates at pH < 8.5, and more so the more acidic the environment 
(Boiadjiev et al., 2004). Most experimental systems add albumin to bind bilirubin, as albumin 
confers stability to bilirubin in solution. Hence, bilirubin toxicity in a system of cultured 
neurons is dependent on variables such as the bilirubin concentration, its binding to albumin 
and other constituents in the culture medium, pH, and temperature (Amit et al., 1990). 
Lowering the bilirubin/albumin molar ratios < 1 not only prevents aggregation of bilirubin, 
but also largely prevents bilirubin toxicity in cell cultures (Cowger, 1971;Lie & Bratlid, 
1970;Schiff et al., 1985).
Hayward et al showed that in incubation medium containing 12.5 - 150 μM 
bilirubin with bilirubin/human serum albumin (HSA) molar ratio (MR) of 1.5 and 3, loss of 
bilirubin due to aggregation was < 10 % after 24 h. Cellular uptake of bilirubin in a human 
neuroblastoma cell line was “considerable” after 90 min, and the authors concluded that the 
preferred bilirubin/albumin ratios for in vitro toxicity studies were between 1.5 and 3 
(Hayward et al., 1987). A later study by the same group showed that the uptake of bilirubin in 
neuroblastoma cells was dose dependent and linear at a bilirubin/HSA MRs of 1.5 and 3, 
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where uptake was defined as the total amount of bilirubin associated with the cells including 
both surface bound and (possibly) internalized bilirubin. By lowering the pH from 7.8 to 7.4 
and 7.0 bilirubin uptake was enhanced 3 and 10 times respectively. 35 - 125 μM bilirubin 
(bilirubin/ HSA 0.8 - 1.5 molar ratio) and pH 7.4, induced toxicity dependent on the 
bilirubin/albumin ratio, bilirubin concentration, and the duration of exposure (Amit et al.,
1990).
Based on these findings, we performed initial experiments with bilirubin/BSA 
MRs of 1.5 and 3. We found that bilirubin at both ratios dose-dependently impaired MTT 
reduction assays over a wide concentrations range (0.66 - 250 μM) measured at 24 h (paper 
II). Differences in the toxic effects between the two MRs were significant; however, 
differences were smaller than anticipated, possibly due to increased aggregation of bilirubin 
with MR 3. We therefore chose MR 1.5 for our later experiments, and kept pH at a slightly 
supra-physiological level (7.59-7.52 over the first 24 h) to further limit bilirubin aggregation.
Bilirubin has a lower affinity for BSA than HSA (Zucker & Goessling, 2000). On the other 
hand, BSA-bound bilirubin was found to have slower dissociation rates than HSA-bound 
bilirubin in cultured hepatoma cells (Zucker & Goessling, 2000). The exact impact of these 
differences is unclear, but the only study which has compared the effect of BSA vs. HSA on 
bilirubin toxicity did not find differences in the toxic effects of bilirubin (Cowger, 1971). In 
our experiments, light-microscopic evaluation showed a slight tendency to aggregation at all 
concentrations  5 μM (paper II). However, even in medium containing 25 μM bilirubin, the 
overall impression was the one of a homogenous bilirubin containing solution with only 
dispersed bilirubin aggregates. A slightly greater tendency for aggregation was found with 
MR 3:1. 0.66 μM bilirubin without albumin was highly aggregated in our experiments. It 
must be added that light-microscopy certainly has limitations, and it is not sensitive enough to 
discover micro-aggregation. Despite the limitation of not knowing the fraction of unbound 
bilirubin, this model proved reliable in reproducing a graded toxic response.
7.4 Significance of nuclear morphological changes
Changes in nuclear morphology were evaluated with a fluorescence staining method as 
described in “Methods” of paper II, III and IV. In general, cells remained adherent to the dish 
during the experiments, and detached nuclei accounted for less than 2 % of the total cell 
count. Pictures were taken from randomly selected areas with medium cell density. The 
densest areas were impossible to count, so that areas of lesser density had to be selected. A 
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potential problem is the possible bias from the person who selects the areas for counting. This 
selection bias was reduced by the mounting of the camera at an angle that did not yield the 
same picture as seen in the middle of the view of the microscope. In that way it was not 
possible to select solitary areas for photographing, but it was possible to avoid the densest 
aggregates.
The combination of the two fluorescent dyes, Hoechst 33342 and EH, was used 
to assess nuclear morphology and membrane integrity. Hoechst 33342 stains the nuclei of all 
living and dead cells, while nuclei of cells with damaged cell membranes, as seen in necrosis, 
are stained by EH. The detection of necrosis was based on the release of lactate 
dehydrogenase (LDH) and uptake of ethidium homodimer (EH) into condensed nuclei (paper 
II). These findings both suggest disintegration of the cell membrane and were seen in 
virtually all cells after treatment with very high bilirubin concentrations (100 μM). We 
defined as apoptotic those cells which after staining with the combination of were stained 
exclusively with Hoechst suggestive of an intact cell membrane, and 1) developed chromatin 
condensation in the shape of a pycnotic rounded mass without disruption of the cell 
membrane or 2) nuclear fragmentation observed as chromatin condensation into the shape of 
lobuli or separate fragments. These definitions have previously been used by our group 
(Almaas et al., 2003) and others (Cregan et al., 2002;Hamabe et al., 2000;Nicotera et al.,
1999). We defined fragmentation as the occurrence of at least two distinct lobuli. In our 
experiments nuclear fragmentation was dependent on the action of caspases, as the general 
caspase inhibitor zVAD.FMK almost completely inhibited nuclear fragmentation induced by 
bilirubin or STS. Condensed nuclei (without disrupted membrane) occurred as the result of 1)
toxicity mediated by the NMDA receptor (as treatment with MK-801 reduced this phenotype, 
paper III), 2) neurons exposed to bilirubin or STS and treated with ZVAD.FMK (paper II), or 
3) apoptosis caused by long-term serum deprivation which could be prevented by caspase 
inhibitors (paper IV, data not shown).
Due to the absence of phagocytosis in neuronal cultures, eventually the cell 
membrane of apoptotic cells also disintegrates to allow staining with EH, so called 
“secondary necrosis” (Kaal et al., 1998). A limitation of the present studies was that this 
secondary necrosis of apoptotic condensed nuclei was indistinguishable from primary 
necrosis, and may have resulted in an overestimation of "necrotic” cell death, appearing as 
condensed nuclei with disrupted membrane, and a possible underestimation of apoptotic 
condensed nuclei. Also neurons displaying fragmented nuclei underwent secondary necrosis, 
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however, these cells were counted as fragmented irrespective of uptake of EH, as apoptotic 
nuclear fragmentation was thought to reflect the principal cell death mode.  
All cells were counted by the principal investigator (Hankø). In all experiments a 
subset of cells were counted by an independent investigator (Almaas). A total of 2000 cells 
from the three studies (paper II, III, IV) were counted to an inter-observer agreement of 95-96 
%. The principal investigator had a slight tendency to judge more cells as being condensed vs. 
both undamaged and fragmented. A worst case scenario may have resulted in an over-report 
of condensed nuclei, however, not of more than 5 %. Secondary necrosis may have resulted in 
an underestimation of primary condensed nuclei, so that this bias does not affect the results in 
the same direction. 
A B
Figure 4. The combination of the two fluorescent dyes Hoechst 33342 and Ethidium 
Homodimer (EH) was used to assess nuclear morphology and membrane integrity 
respectively.  (A) Predominantly healthy control cells not exposed to bilirubin. (B) Cells 
exposed to 5 μM bilirubin for 6 h, and photographed 96 h after removal of bilirubin. 
Undamaged nuclei (white arrow) and condensed nuclei with preserved cellular membranes 
(blue arrow) and fragmented nuclei (green arrow) considered apoptotic, were stained by 
Hoechst 33342 only. Condensed nuclei with disrupted membranes displaying uptake of EH 
(red arrow) were considered necrotic.
7.5 MTT reduction assays 
The rate by which cells reduce MTT is a well established method to evaluate cell viability and 
proliferation. MTT is a tetrazolium salt which is actively transported into cells by endocytosis 
(Liu et al, 1997).  A variety of sub-cellular fractions, including the cytoplasm, mitochondria, 
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and non-mitochondrial membranes including endosomes and lysosomes are capable of 
reducing MTT predominantly by an NADH-dependent mechanism. Reduced MTT is 
thereafter actively transported to the cell surface by exocytosis (Liu et al., 1997). The crystals 
are solubilized with DMSO and measured by a spectrophotometer.  
Impairment of all these steps may affect the MTT reduction assays, and the 
capacity of MTT to cross intact plasma membranes is an important experimental variable 
(Bernas & Dobrucki, 2000). Impaired MTT reduction is not always associated with cell death. 
Several studies on ȕ-amyloid-mediated cell death have shown that impaired MTT reduction 
represents an early indicator of cell injury without necessarily causing cell death (Patel et al.,
1996;Shearman et al., 1995). In astrocytes, a 4 h exposure to a moderate bilirubin 
concentration (17 ȝM) impaired endocytosis and MTT reduction without affecting the 
cytoskeleton, suggesting interaction of bilirubin primarily at the plasma membrane, while 
higher bilirubin concentrations (171 ȝM) also disaggregated the cytoskeleton (Silva et al.,
2001a). In our experiments evaluation of MTT assays and nuclear morphology at 6 h 
suggested that the development of apoptotic morphologies were later events than diminished 
MTT reduction (paper II and IV), compatible with the idea that interaction with the plasma 
membrane is an early event in bilirubin toxicity. In the absence of co-treatments the 
proportion of undamaged nuclei showed similar results as MTT assays at all time points  24 
h for treatment with bilirubin, staurosporine, and serum deprivation (paper II and paper IV). 
These results are in good agreement with previous studies using NT2-N neurons (Almaas et
al., 2003;Itoh et al., 1998).
MTT assays and nuclear morphology in cells receiving anti-apoptotic treatment 
In our studies, MTT assays did not always show the same degree of protection by co-
treatments as found by evaluation with nuclear morphology (paper III and IV). In neurons 
subjected to bilirubin and serum deprivation for 48 h (paper III), serum deprivation alone 
(102 h), or a 6 h bilirubin exposure with subsequent rescue and evaluation 96 h thereafter 
(paper IV), the protective effects of treatments found by morphological evaluation were either 
not reflected in the MTT assays (treatment with caspase inhibitors) or to a considerably lesser 
degree (treatment with MK-801). The explanation for this discrepancy is not clear. Our 
findings may suggest that moderate insults cause cell death in a subset of neurons which is 
prevented by blockade of the cell death pathways involved, but that treatment can not prevent 
the overall impairment on MTT metabolism in the entire neuronal population.  
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These results are in line with a study on rat cerebellar granule neurons exposed to potassium-
deprivation where caspase inhibitors prevented apoptotic morphologies, but did not improve 
MTT reduction (Harada & Sugimoto, 1998). Furthermore, Lobner found that MTT assays do 
not always correctly quantify neuro-protective effects, and the usefulness of MTT assays in 
determining effects of co-treatment is dependent on the inducer of cell death (Lobner, 2000). 
In paper III cells subjected to staurosporine and co-treatment with caspase inhibitors, MTT 
reduction and the proportion of undamaged neurons showed similar results (paper III).  
7.6 The impact of serum deprivation in the present studies 
Serum deprivation is a cytotoxic environmental change that has been shown to induce cell 
death in various cultured cells (Deshmukh & Johnson, 1997;Kariya et al., 2002). The detailed 
mechanisms of the execution of cell death in serum-deprived cells are uncertain, but caspase-
activation is believed to play an important role in the execution of cell death in some 
(Batistatou et al., 1993;Deshmukh & Johnson, 1997;Stefanis et al., 1996), but not all cell 
lines (Hamabe et al., 2000). A 6 h serum deprivation caused moderate impairment of the 
MTT assays. After subsequent neuronal rescue with washout of the serum free medium and 
re-addition of serum containing medium, MTT reduction did not deteriorate further and no 
delayed cell death was found after 96 h (paper IV). After a 102 h serum deprivation, cell 
death was substantial (paper IV), and concomitant exposure to UCB (1, 5 and 25 ȝM) caused 
dose-dependent bilirubin toxicity additional to the effects of serum deprivation. To elucidate 
the mechanisms of cell death induced by serum deprivation, we performed additional 
experiments on neurons exposed to serum deprivation alone. Cell death induced by serum 
deprivation for 102 h was reduced by co-treatment with caspase inhibitors, but not by 
treatment with the NMDA-receptor antagonist MK-801 (paper IV). Similar experiments after 
a 24 h serum deprivation (control experiments, paper III) showed treatment effects of caspase 
inhibitors or MK-801.
Our findings indicated that serum deprivation and bilirubin may have additive 
toxic effects. Serum deprivation may contribute to cell death by a late induction of caspase-
dependent cell death pathways. In our model of concurrent long term serum deprivation and 
bilirubin, serum deprivation definitely had impact on the cell death pathways involved after a 
102 h (paper IV). In retrospect, the additive effects of serum deprivation at earlier time points 
(24 and 48 h) cannot be ruled out (paper II and III). The impact of a 6 h serum deprivation on 
rescued neurons at evaluation 96 h after neuronal rescue was assumed to be minor (paper IV).  
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8. DISCUSSION OF RESULTS 
8.1 P-gp inhibitors and bilirubin entry into the brain 
Watchko et al showed that brain bilirubin content was almost two fold higher in knockout 
mice devoid of P-gp than in wild type animals after an iv injection of bilirubin (Watchko et
al., 1998). In paper I a similar experimental procedure was used to induce bilirubin entry into 
the brain ten minutes after the injections of different P-gp inhibitors. Ceftriaxone is both a P-
gp inhibitor and a highly potent displacer of bilirubin. As the brain/bilirubin ratio increased 
more in ceftriaxone-treated animals (to 237 %) than in knock out mice devoid of P-gp 
(Watchko et al., 1998), the bilirubin-displacing property of the drug apparently had an 
additive impact on bilirubin entry into brain. The increase in total brain bilirubin uptake after 
treatment with drugs without significant bilirubin-displacing properties varied from 24% 
(erythromycin not significant) to 66 % (rifampin) compared to control animals pre-treated 
with saline. This is similar to the increase in brain bilirubin induced by other known risk 
factors such as hyperosmolarity or hypercapnia, where brain bilirubin increased by 39 % and 
70 % respectively (Hansen TWR et al., 1989). The increased entry into the brain was, 
however, considerably less than the one reported for P-gp substrates with a higher affinity for 
P-gp than bilirubin, such as ivermectin (2.5- fold) or rhodamine (3-fold) after P-gp inhibition 
with Cyclosporine A (Marques-Santos et al., 1999).
In experimental animal models where the permeability of the BBB has been 
increased by inducing hyperosmolarity or hypercapnia, the regional distribution of brain 
bilirubin has shown a poor correlation with the one seen in kernicteric brains of human 
neonates (Hansen TWR et al., 1989;Hansen, 1996;Levine et al., 1982). In our experiments 
the regional distribution patterns in control rats and ceftriaxone-treated rats were similar in 
that the cerebellum showed enhanced uptake compared to most other brain regions. However, 
other brain areas which are severely affected in kernicteric infants such as the hippocampus or 
the basal ganglia did not show altered bilirubin uptake compared to other brain regions. In 
rats pre-treated with rifampin, an agent without known bilirubin-displacing properties, the 
bilirubin content was significantly lower in the cortex compared to the cerebellum and the 
medulla. If P-gp-mediated bilirubin efflux at the BBB made an important contribution to the 
regional distribution pattern of bilirubin in the brain, it is likely that treatment with P-gp 
inhibitors would provide an increased entry into the areas of the brain which are protected 
from bilirubin by P-gp; e.g. treatment with P-gp inhibitors would more potently enhance the 
entry of bilirubin into the frontal cortex than into the cerebellum. Taken together, treatment 
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with P-gp inhibitors had limited impact on the regional distribution pattern of brain bilirubin 
in this model. The observed changes did not suggest that membrane transport proteins like P-
gp are responsible for the regional distribution pattern of brain bilirubin found in kernicterus. 
 Our results are compatible with two studies by Drion et al where pre-treatment 
with the second generation P-gp blocker PSC or verapamil increased the distribution volume 
of colchicines (a cytotoxic drug) by 8- and 4- fold respectively in eight grey areas of the brain 
(Drion et al., 1996;Drion et al., 1997). The entry of colchicine was similarly enhanced in all 
areas of the brain. A role for P-gp in determining the distribution pattern can not be 
completely ruled out from the present studies. The full potential of P-gp inhibition may not 
have been reached in the present model, as it is unknown whether P-gp was fully saturated 
with P-gp inhibitor in all areas of the brain.
Up-regulation of P-gp in humans is similar to the one found in rodents (as 
discussed previously). In the human brain P-gp is expressed in capillary endothelial cells, 
astrocytes, and choroid plexus epithelium by 23 weeks of gestation (Tsai et al., 2000). At 
term the distribution pattern is similar to the one found in the adult brain, however, with 
markedly less density (Tsai et al., 2000). Hence, the ontogeny of P-gp suggests that the 
effects of P-gp inhibitors are less in newborn rats than in young adult animals as used in the 
present study. Information on the ontogeny of OATp and MRP in newborn animal species or 
humans is to our knowledge virtually non-existing. Due to the limited knowledge on the 
ontogeny of membrane transport proteins, it is difficult to extrapolate our findings to the 
jaundiced newborn human. It would be worthwhile to verify our findings in newborn animals, 
however due to their small size studies requiring iv infusions or blood sampling in newborn 
rodents is technically extremely difficult. This suggests the use of different animal models in 
future studies. 
MRP is found at the BBB in humans and rodents (Liang & Aszalos, 2006;Tamai 
& Tsuji, 2000), and OATp is expressed in rat brain both at the BBB and in the choroid plexus 
(Gao et al., 1999;Gao et al., 2000). Unconjugated bilirubin is a substrate for MRP (Pascolo et 
al., 2001) and organic anion transport protein (OATp) (Cui et al., 2001). As many P-gp 
inhibitors, among them verapamil and rifampin are also MRP inhibitors (Courtois et al.,
1999;Cullen et al., 2001), it can not be claimed that the drugs used in the present study 
exerted their function exclusively at the P-gp inhibitor. Drug inhibition of OATp by the drugs 
used in our experiments is to our knowledge not studied.
A possible contribution of membrane transport proteins in the pathogenesis of 
kernicterus may have important implications. Based on our findings Hascoet proposed that 
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since genetic polymorphism in the human P-gp gene has been demonstrated, this could 
explain the susceptibility of some newborns to bilirubin toxicity. It is possible that specific 
genetic markers may predict susceptibility to bilirubin toxicity similar to the role of genetic 
markers as means to improve anti-leucemic or anti-retroviral therapy (Hascoet, 2003).
To conclude, we have shown that treatment with several drugs known to inhibit 
P-gp may cause increased entry of bilirubin into the brain of young adult rats. The effect of 
treatment on the distribution pattern of brain bilirubin was modest and the relevance with 
respect to the bilirubin distribution pattern as seen in kernicterus is uncertain. We speculate 
that drugs inhibiting P-gp or other membrane transport proteins may increase the risk of 
bilirubin encephalopathy in the hyperbilirubinemic infant. However, the limitations of our 
study, such as the limited knowledge on the ontogeny of membrane transport proteins, the 
overlap in substrate specificities of the different transport proteins, and the use of inhibitors 
that are not entirely specific for P-gp, highlight the need for robust models that allow studies 
of the specific roles of membrane transport proteins in the entry and elimination of bilirubin 
in the brain of newborns. 
8.2 Short-term exposure to bilirubin results in recovery of function or delayed cell death  
Some studies have suggested that the risk of significant neurological abnormalities correlates 
with the duration of hyperbilirubinemia (Devries et al., 1985;Ozmert et al., 1996). Also, 
clinical studies suggest that early stages of bilirubin encephalopathy are reversible (Paludetto 
et al., 2002;Shapiro, 1993), but reversibility of bilirubin toxicity has never been shown in 
intact neuronal cultured cells. Reversibility of an apoptosis-inducing stimulus has been 
extensively studied in neuronal growth factor (NGF)-deprived neurons. Sympathetic neurons 
deprived of NGF are capable of resuming neuronal growth and metabolism when NGF is 
added back into the cultures (Deshmukh et al., 1996;Deshmukh et al., 2000). We found that 
removal of bilirubin and re-incubation in serum-containing medium provided recovery as 
measured with MTT assays and nuclear morphology in neurons exposed to 1 μM bilirubin for 
6 hours (paper IV). Long-term exposure to 1 μM bilirubin, however, significantly increased 
cell death (compared to serum deprivation alone), showing that this bilirubin concentration 
may induce permanent cell injury if the exposure time is prolonged.  
As discussed elsewhere, interference with several different steps in MTT 
metabolism may impair MTT reduction. The capacity of MTT to cross intact plasma cell 
membranes is an important experimental variable (Bernas & Dobrucki, 2000). In astrocytes, a 
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4 h exposure to moderate bilirubin concentrations (17 μmol/l) impaired endocytosis and MTT 
reduction without affecting the cytoskeleton, suggesting interaction with MTT at the plasma 
membrane (Silva et al., 2001a). Evidence suggests that injury to the cell membrane is a key 
factor in bilirubin toxicity (Eriksen et al., 1981;Vazquez et al., 1988). After the initial 
formation of a bilirubin anion-phospholipid complex at the cell membrane, bilirubin has a 
tendency to take up H+ ions and form bilirubin acid leading to cell membrane destruction 
(Eriksen et al., 1981;Vazquez et al., 1988). As our experiments were conducted at slightly 
alkaline pH (pH 7.5 -7.6) the tendency to form membrane-aggressive bilirubin acid may have 
been modest. After the bilirubin washout and addition of the original serum-containing 
medium (paper IV) bilirubin may have been removed from the cell membrane by its binding 
to serum constituents consistent with previous studies (Brito & Brites, 2003;Cowger, 
1971;Vazquez et al., 1988).
In cultured hepatoblastoma cells bilirubin crosses the cell membrane by a 
mechanism involving spontaneous diffusion (Zucker & Goessling, 2000). While such a 
phenomenon has not been firmly established in neurons, one in vivo study strongly suggested 
that bilirubin crosses plasma membranes (Hansen et al., 2001). An additional mechanism of 
possible importance is that bilirubin may be metabolized in the mitochondria by a process of 
oxidation (Hansen & Allen, 1996a;Hansen & Tommarello, 1998). However, the possible 
clinical impact of such a mechanism in the brain is not known. Furthermore, it has not been 
shown in cultured cells.
In vitro studies have shown reversibility of certain bilirubin-mediated effects 
like phosphorylation of synapsin in synaptosomes from rat brain (Hansen et al., 1988), and 
glutamate uptake in cultured astrocytes (Silva et al., 1999). Amit and co-workers reported that 
incubation with 25–100 μM bilirubin (bilirubin:HSA molar ratio 1.5) for 1-2 h and rescue 
with serum free medium in a human neuroblastoma cell line caused delayed and near 
complete cell death after 24 h, leading to the conclusion that bilirubin toxicity was a 
“progressive and irreversible process” (Amit et al., 1989b). The main reason for the different 
conclusions from our study is likely to be the high bilirubin concentration used. Results 
obtained with 25 μM bilirubin were similar in both studies. In a different model the addition 
of albumin to a 1.1:1 molar ratio (BSA:bilirubin) in L-929 cells exposed to 25 μM bilirubin 
for 1-30 min resulted in the extraction of a significant  proportion of the bilirubin from the 
cells, but it did not prevent subsequent loss of cell viability (Cowger, 1971). A combination 
of different factors may have resulted in reversal of bilirubin toxicity in our model. These 
factors may include 1) the use of a low bilirubin concentration (1 ȝM), 2) the conduct of the 
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experiments at slightly alkaline pH, 3) the use of the original serum-containing medium after 
the 6 h bilirubin-exposure, which may have resulted in i) an extraction of bilirubin from the 
neuronal surface due to binding of bilirubin to serum constituents, ii) optimal conditions for 
cellular metabolic recovery post- exposure, and 4) long recovery time after bilirubin exposure 
(96 h).
To conclude, short term exposure to bilirubin in human NT2-N neurons may be 
followed by recovery of function or delayed neuronal death. These effects are dependent on 
the bilirubin concentrations and the duration of exposure. Our findings are compatible with 
clinical studies demonstrating that permanent neurological sequel may be related to the 
magnitude and duration of bilirubin exposure, and that the effects of bilirubin on the brain 
may be reversible. Our model may be suitable to study reversible effects of bilirubin toxicity 
in vitro.
8.3 Bilirubin induces apoptosis and necrosis in human NT2-N neurons
Several studies have found that bilirubin induces concentration- and time-dependent injury in 
cultured cells (Akin et al., 2002;Amit et al., 1989a;Amit et al., 1989b;Cowger, 1971;Grojean 
et al., 2000;Silberberg et al., 1970;Silva et al., 2001b). Many of these studies were either 
conducted on non-neuronal cells or predate the recognition of apoptosis. Our studies showed 
that bilirubin induced a concentration-dependent injury as measured with MTT assays (paper 
II and IV) and nuclear morphology (paper IV). Bilirubin concentrations  25 ȝM caused 
apoptosis, and in neurons exposed to  10 ȝM bilirubin, apoptosis was the major form of cell 
death. Very high bilirubin concentration (100 ȝM) induced a rapid decline in MTT reduction 
and complete necrotic cell death within 24 h, however, even low and moderate insults caused 
necrosis within 24 h in a subpopulation of neurons (paper II).
Our studies are the first to investigate the relation between bilirubin-induced 
apoptosis and necrosis in a human neuronal cell line. Species differences have been shown to 
play a role in the response to cell death inducing stimuli (Nitsch et al., 2000), and studies on 
stillborn infants have suggested that the fraction of apoptotic cells may be higher in human 
tissues than suggested from animal experiments (Edwards et al., 1997). Silva et al found that 
a short bilirubin exposure (4 h) to 17 μM bilirubin (bilirubin:HSA molar ratio 3:1) resulted in 
similar degrees of apoptosis and necrosis in cultured astrocytes from fetal rats. Necrosis 
predominated over apoptosis at higher bilirubin concentrations (86 μM) and longer exposure 
times (22 h). In neurons, evaluated at 4 h only, the proportions of necrosis and apoptosis were 
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similar (Silva et al., 2001b). Another study by the same group showed that a 4 h exposure to 
86 μM bilirubin (bilirubin/HSA = 3:1) induced apoptosis in 25 % of cultured neurons from 
fetal rat brain cortex. The proportion of apoptotic cells decreased with lower bilirubin/HSA 
ratios, indicating that the prevalence of apoptosis increased with higher concentrations of 
unbound bilirubin (Rodrigues et al., 2002a). After exposure to low bilirubin concentrations 
(0.5 μM without albumin vehicle) for 96 h, apoptosis was slightly more prevalent than 
necrosis (16 and 12 % respectively) in primary cultured neurons from embryonic rat forebrain 
(Grojean et al., 2000). Seubert et al investigated bilirubin-induced cell death (1-100 μM 
bilirubin and a fixed concentration of 40 μM BSA in 10 % serum containing medium) in 
three different murine hepatoblastoma cell lines after a 24 h exposure. They found that both 
apoptotic and necrotic cell death increased in a concentration-dependent fashion, with a 
predominance for necrotic cell death at higher bilirubin concentrations (Seubert et al., 2002). 
 Our findings are in agreement with previous studies on non-human cells 
showing that apoptosis and necrosis may co-exist after bilirubin-mediated injury. However, 
our results may suggest that cells of human origin differ somewhat from primary cell cultures 
from rodents. In human NT2-N neurons apoptosis was much more prevalent than necrosis 
after exposure to low bilirubin concentrations. Furthermore, apoptosis was a late event and 
occurred more than 6 h after the onset of bilirubin exposure. Our findings are well in 
accordance with the classical paradigm that toxic stimuli may induce necrosis or apoptosis 
depending on the intensity of the insult. Typically, necrotic cell death is an early event in a 
subpopulation of cells while apoptosis is a slower process in a different subset of neurons 
(Bonfoco et al., 1995). This has been confirmed in studies caused by different insults such as 
glutamate (Ankarcrona et al., 1995), acidosis (Ding et al., 2000) or methyl mercury (Castoldi 
et al., 2000) in vitro,  and hypoxia-ischemia (Beilharz et al., 1995;Martin et al., 1998) in 
animal models in vivo. Furthermore, the temporal evolution of apoptosis and necrosis in our 
studies was consistent with the ones found after HI injury (Northington et al., 2001b) and 
excitotoxic injury (PorteraCailliau et al., 1997) in neonatal rodents in vivo.
The execution of apoptosis is an energy-requiring process. In neurons treated 
with 10 μM bilirubin, i.e. bilirubin concentrations inducing cell death predominantly as 
apoptosis, metabolic activity was maintained as measured with MTT reduction throughout the 
observation periode (paper II). This finding was compatible with preserved energy levels in 
cells undergoing apoptosis. It has been claimed that MTT reduction at least in part reflects 
mitochondrial activity and the production of ATP (Kaneko et al., 1995), however, a good 
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correlation between MTT assays and the energy status of the cell has not been firmly 
established (Harada & Sugimoto, 1998;Kaneko et al., 1995).
Apoptotic nuclei could be divided into two distinct groups by their 
morphological appearance. Nuclear condensation was an early event and the proportion of 
condensed nuclei did not increase after 24 h, while nuclear fragmentation first occurred at 24 
h and continued to increase for at least up to 48 h (paper II). Nuclear condensation was (at 
least in part) the result of excitotoxic cell death, as it could be reduced by the NMDA receptor 
blocker MK-801 (paper III), and seemed to be independent of caspases. Nuclear 
fragmentation was mediated by caspases, and was nearly completely prevented by high dose 
caspase inhibitors (paper III). Our findings suggest that bilirubin may induce both caspase-
dependent and caspase–independent apoptosis in NT2-N neurons, and that these two 
pathways may co-exist in cultured neurons, as will be discussed in the following chapters. 
To conclude, our results are in line with the literature showing that apoptosis and 
necrosis may co-exist after bilirubin-induced injury both in vivo, and in neuronal cultures in
vitro. Our results suggest that cell death induced by low and moderate bilirubin-
concentrations is predominantly apoptotic in NT2-N neurons. Both caspase independent- and 
caspase dependent apoptotic pathways appear to be involved. 
8.4 Caspases and caspase inhibition in bilirubin-induced cell death  
The execution of caspase-mediated apoptosis follows a cascade of events resulting in the 
activation of the executioner caspases -3, -6, or -7, where caspase-3 has been identified as a 
major executioner caspase (Nicholson et al., 1995;Racke et al., 2002). Our results (paper II, 
III and IV) provide evidence for a role of caspase-activation in bilirubin-induced death in 
NT2-N neurons. Indirect measures of caspase-3 activation like PARP cleavage and 
oligonucleosomal DNA fragmentation occurred after exposure to 5 ȝM bilirubin, but not after 
exposure to higher bilirubin concentrations (paper II). Direct measurement of activated 
caspase-3 showed a moderate increase after exposure to 5 μM bilirubin at 6 h (230 % 
compared to base-line values), but had returned to base-line values at 24 h (paper III), while 
25 μM bilirubin did not activate caspase-3 (results not shown in paper III). In two different 
studies on primary cell cultures from rodents bilirubin induced a concentration-dependent 
caspase-3 activation where caspase-3 activation was maximal after exposure to high bilirubin 
concentrations (86 μM and 50 μM bilirubin respectively) (Rodrigues et al., 2002a;Seubert et 
al., 2002). Hence, in our studies caspase-3 activation appeared to be less prominent at higher 
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bilirubin concentrations than previously reported from studies on primary cell cultures from 
rodents. This finding was consistent with the concentration-dependent effects of bilirubin on 
apoptotic morphologies as discussed in the previous chapter. 
Substrate preferences of the different caspases have been exploited for the 
development of caspase inhibitors. Caspase inhibitors are peptides that compete for caspase 
binding with the substrates of activated caspases (Degterev et al., 2003). Despite effects on 
nuclear morphology, treatment with caspase inhibitors enhanced neuronal survival only to a 
very limited extent, and this effect was not reflected in the MTT assays (paper III and IV). 
Experiments with long term bilirubin exposure combined with serum deprivation (96 h) 
showed effects of both caspase inhibitors, but our results suggest that long term serum 
deprivation affected these results (paper IV). Only one previous study has investigated the 
effects of caspase inhibition in bilirubin-induced injury. Grojean et al found that both 
caspase-1 and caspase-3 inhibitors completely abolished both apoptosis and necrosis after 
treatment with 0.5 μM bilirubin for 96 h in cultured cortical rodents from fetal rats (Grojean 
et al., 2000). This study was undertaken under serum free conditions, however, serum was 
replaced by growth factors and hormones to eliminate the impact of serum deprivation. Both 
species differences and the low bilirubin concentrations used in their study may explain the 
differences between their results and ours. Our data do not exclude the possibility that caspase 
inhibitors may prevent cell death caused by very low bilirubin concentrations. 
Evidence from in vitro studies suggests that caspase inhibitors may induce only 
transient protection in most, if not all cell lines (for reviews see Kroemer & Martin, 
2005;Stefanis, 2005). Several investigations have shown that nuclear fragmentation is 
prevented when caspases are inhibited, however, the cells die from caspase-independent 
apoptosis (Cregan et al., 2004;Daugas et al., 2000). Alternative caspase-independent 
pathways are activated when caspases are inhibited or a parallel pathway becomes dominant 
in the presence of caspase inhibitors (for review see Stefanis, 2005). AIF may play a role in 
the execution of this cell death as caspase inhibitors may block caspase activity, but not AIF 
translocation from the mithochondrion to the nucleus (Cregan et al., 2002). Caspase 
inhibition may also cause a switch from apoptosis to necrosis (Green & Kroemer, 
1998;Hirsch et al., 1997), however, caspase inhibition had no effect on the proportion of 
necrotic cells in our assays (paper III). 
It is generally held that the intrinsic pathway is the principal caspase-dependent 
apoptotic pathway in neurons (Stefanis, 2005). Our data could not determine whether 
bilirubin causes caspase dependent apoptosis by the intrinsic or extrinsic apoptotic pathway. 
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The possible contribution of the extrinsic apoptotic pathway is interesting in light of data 
suggesting that bilirubin may exert its principal effect on the cellular plasma membrane. 
However, several authors report that bilirubin induces caspase-mediated apoptosis through 
the intrinsic apoptotic pathway (Rodrigues et al., 2000;Rodrigues et al., 2002a;Seubert et al.,
2002). In colon cancer cells cells bilirubin induces apoptosis by activating caspase-3, caspase-
9 and cytochrome c without activating caspase-8, strongly suggesting that apoptosis was 
mediated by the intrinsic pathway (Keshavan et al., 2004).
To summarize, our results demonstrate that caspases are activated and play a 
role in the execution of bilirubin-mediated cell death in a neuronal cell line of human origin.  
Caspase-3 is activated after exposure to low bilirubin concentrations, but treatment with 
caspase inhibitors had only a very modest apoptosis reducing effect (paper III). Caspase 
inhibition did, however, have an impact on apoptotic nuclear morphologies and DNA-
degeneration patterns. 
8.5 Excitotoxicity in bilirubin-induced cell death
Treatment with MK-801 significantly enhanced neuronal viability as measured by the 
proportion of undamaged nuclei in a model of continuous exposure to bilirubin and serum 
deprivation after 48 (paper III) and 102 h (paper IV). In a different model, a 6 h exposure to 5 
ȝM bilirubin followed by removal of bilirubin, MK-801 significantly increased the proportion 
of undamaged nuclei 96 h thereafter (paper IV). In the MTT assays significant protective 
effects were, however, only found after continuous bilirubin exposure for 102 h (paper IV). 
Our results indicate that treatment with MK-801 may reduce cell death, but the lack of effect 
on neuronal function as suggested by the MTT assays raises doubt as to whether MK-801 
restores all aspects of neuronal function. An alternative understanding is that neurons may 
recover (or die) after the observation period. Experiments on serum-deprived neurons have 
showed that functional recovery after an insult may take up to two weeks (Deshmukh et al.,
1996).
Our findings confirm that bilirubin exerts its toxicity by excitotoxic mechanisms 
as previously found both in vivo (Hoffman et al., 1996;McDonald et al., 1998) and in vitro 
(Grojean et al., 2000). MK-801 reduced cell death more potently than caspase inhibitors, and 
this effect was not biased by the impact of serum deprivation (paper IV). Based on the 
complete protection by treatments with caspase-1 inhibitors, or caspase-3 inhibitors, or MK-
801 on necrotic and apoptotic cell death Grojean et al concluded that excitotoxicity was 
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mediated by caspase-dependent pathways. Our findings strongly suggest that NMDA 
receptor-mediated apoptosis was not mediated by caspases. First, the most prominent effect of 
treatment with MK-801 was the reduction of apoptotic condensed nuclei without affecting the 
proportion of fragmented nuclei or oligonucleosomal DNA-laddering. Second, treatment with 
MK-801 concomitantly with bilirubin exposure had no influence on caspase-3 activation, and, 
third, combined treatment with MK-801 and a pancaspase inhibitor synergistically reduced 
apoptosis, suggesting that these agents exerted their effects on separate apoptotic pathways 
(paper III).  
The current understanding is that in most cases excitotoxicity is not mediated by 
caspases (Cheung et al., 2005;Lankiewicz et al., 2000;Wang H et al., 2004). If caspases are 
not responsible for mediating excitotoxicity, what is? Increased calcium concentrations may 
activate a group of proteases called calpains which seem to act upstream of the mitochondria. 
Calpains cleave multiple substrates involved in cell death (Stefanis, 2005), and may execute 
cell death at least in part by an AIF-mediated mechanism (Polster et al., 2005).
Also, studies on NMDA receptor mediated cell death both in vivo and in vitro, have shown 
that AIF may translocate from the mitochondria to the nucleus (Wang H et al., 2004). In 
several models of cell death AIF has been shown to induce apoptosis as nuclear 
condensation (Cheung et al., 2005;Cregan et al., 2002;Wang H et al., 2004). As this 
apoptotic phenotype was reduced by the NMDA receptor antagonist MK-801 in our 
experiments, our data are compatible with a role for AIF in bilirubin-induced apoptosis. 
However, a contribution of AIF in bilirubin-mediated apoptosis has never been addressed. 
The possible involvement of cell death effectors such as AIF or Endonuclease G in bilirubin 
toxicity needs further clarification. 
Several in vivo investigation in adult rodents have shown synergistic effects of 
treatment with caspase inhibitors and NMDA receptor antagonists in models of hypoxic 
ischemic encephalopathy (HIE) (Ma et al., 1998;Schulz et al., 1998) and trauma (Liang et al.,
2003). In these investigations synergistic treatment effects were attributed to the inhibition of 
separate cell death pathways by caspase inhibitors and NMDA receptor antagonists. This may 
be different in immature rats where NMDA receptor-mediated toxicity may induce caspase-
dependent apoptosis. Injections of NMDA into the striatum of  7 day-old rat pups induced 
neuronal loss accompanied by DNA laddering and caspase-3 activation (Nath et al., 2000). 
Furthermore, in a neonatal rat model of HIE caspase-3 activation was reduced by treatment 
with MK-801 (Puka-Sundvall et al., 2000).
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                        To conclude, we found that excitotoxic mechanisms are involved in bilirubin-
mediated injury in NT2-N neurons in line with prior in vivo and in vitro investigations. 
Excitotoxic cell death pathways were, at least in part, distinct from caspase-mediated 
pathways (paper III), and concurrent inhibition of both pathways provided synergistic 
protection. Furthermore, treatment with MK-801 was more promising than caspase inhibition 
in reducing delayed cell death after a short term exposure to bilirubin. 
8.6 Can treatment with anti-apoptotic agents prevent bilirubin-mediated injury? 
The immature brain may be more susceptible to both excitotoxicity and cell death from 
apoptosis than the adult brain. In the immature brain key elements of apoptosis are 
constitutively up-regulated (Blomgren et al., 2001;Johnston MV et al., 2002). This up-
regulation seems to involve both caspase-3 mediated pathways (Blomgren et al., 2001;Zhu et
al., 2000),  caspase-8 activation compatible with a role for the extrinsic apoptotic pathway 
(Northington et al., 2001a), and AIF (Zhu et al., 2005;Zhu et al., 2007). Also, excitotoxicity 
seems to play a more prominent role in the neonate than in the adult (Blomgren et al.,
2001;Johnston et al., 2002;McDonald et al., 1988).
Extrapolating from human NT2-N neurons to jaundiced newborns is tenuous. To 
date, evidence for bilirubin-induced apoptosis in vivo is confined to light microscopy in the 
Gunn rat animal model of neonatal jaundice and kernicterus (McDonald et al., 1998). 
However, the idea that anti-apoptotic therapies may keep neurons alive for a time sufficient to 
reduce bilirubin-mediated stress and to establish a tissue milieu compatible with long term 
survival and function is worth pursuing. Most of our knowledge on the effects of anti-
apoptotic treatments in the newborn is derived from neonatal models of HIE in rodents. 
Biochemical and neuro-pathological data suggest efficacy of caspase inhibition in reducing 
the neuronal cell death in different neonatal models of HIE in rodents for up to 22 days (for 
review see Northington FJ et al., 2005). However, to date no studies on the effects of caspase-
inhibition in neonatal animal models of HIE have examined the neurological outcome. Also, 
there are contradictory reports with respect to whether or not the inhibition of caspases 
actually improves long term functional outcome in adult models of HIE (Gillardon et al.,
1999;Xu et al., 1999). 
Treatments with the present generation of caspase inhibitors or NMDA receptor 
antagonists in the jaundiced newborn may not be without problems. Caspase inhibitors and 
MK-801 exhibit low penetration into the brain after iv administration and are mostly 
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administered by intra-cerebroventricular injections in research animals (Loetscher et al.,
2001). Both caspases and NMDA receptors have important physiological properties, and to 
interrupt these functions may in itself be harmful (Ikonomidou & Turski, 2002;Kroemer & 
Martin, 2005). Studies with agents combating targets such as MAPK pathways, AIF, PARP, 
and BCL-2 family proteins are upcoming (for reviews see Mehta et al., 2006;Kroemer & 
Martin, 2005).
Two recent studies with minocycline, a second generation tetracycline with good 
penetration into the brain, deserve special attention. Minocycline prevented bilirubin-induced 
cerebellar hypoplasia in the Gunn rat, and it reduced cell death in cerebellar granule neurons 
(Lin et al., 2005).  Furthermore, treatment with minocyclin 15 min prior to recordings 
improved brainstem auditory evoked potentials in jaundiced Gunn rats exposed to 
sulfisoxazole (Geiger et al., 2006). Inhibition of MAPK phosphorylation by bilirubin was 
associated with the neuroprotective effects of minocyclin (Lin et al., 2003). In addition it has 
been shown that minocyclin mediates neuroprotection by blocking the release of apoptogenic 
factors such as cytochrome c and AIF (Lin et al., 2003). 
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9. CONCLUDING REMARKS 
The recognition of apoptosis has resulted in an explosive increase in research on cell death 
mechanisms during the last decade. In this period surprisingly little research has been 
undertaken on the mechanisms of bilirubin-induced cell death compared to for example HIE. 
This may be due to the assumption that bilirubin-induced injury has become rare in the 
industrialized world. However, the apparent resurgence of kernicterus (Ebbesen, 
2000;Johnson et al., 2002), the recent indications of permanent but subtle sequel even in 
patients with moderate hyperbilirubinemia (Grimmer et al., 1999;Soorani-Lunsing et al.,
2001), and concern about whether apparent reversible bilirubin-mediated effects are indeed 
harmless (Maisels et al., 2004), should urge increased efforts to understand the mechanism of 
bilirubin-induced injury. Furthermore, while treatments to reduce elevated bilirubin levels, 
such as phototherapy, have proven effective in reducing elevated TSB levels, evidence is 
lacking that such therapies actually reduce subsequent bilirubin-mediated brain injury 
(Maisels et al., 2004). 
In this thesis we have shown that drugs known to inhibit P-gp may increase 
bilirubin entry into the brain to an extent that may have clinical consequences. Transport of 
bilirubin by membrane transport proteins may be an important mechanism of bilirubin-
mediated injury, and well designed studies to elucidate these mechanisms are warranted. 
Furthermore, it is of vital importance to substantiate that apoptotic cell death in vitro is a 
phenomenon that also occurs in vivo. It is reasonable to believe that new insights into the 
mechanisms of brain injury obtained from basic science investigations will provide new 
treatments for neurological disorders in the future. For an otherwise healthy infant admitted to 
hospital with extremely high TSB levels, a time window for treatment with neuroprotective 
agents may exist prior to the onset of exchange transfusions.  However, before new therapies 
may be put into clinical practice it must be determined whether treatments promote more 
benefit than harm. 
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10. CONCLUSIONS 
1.Administration of drugs known to inhibit P-gp increases the entry of bilirubin into the brain 
at a magnitude of possible clinical significance in young adult rats. Effects on the distribution 
pattern of bilirubin in the brain were modest and not in accordance with a kernicteric staining 
pattern.
2.Short-term exposure to bilirubin may be followed by recovery of function or delayed 
neuronal death in human NT2-N neurons, depending on the magnitude of the insult and the 
duration of exposure. 
3.Apoptosis and necrosis may co-exist after bilirubin-induced injury in NT2-N neurons. 
Apoptosis is the predominant cell death mode after exposure to low and moderate bilirubin 
concentrations.
4.Caspases are activated in bilirubin-induced apoptosis in NT2-N neurons. Treatment with 
caspase inhibitors had a modest or no impact on cell death, however, treatment with caspase 
inhibitors had impact on nuclear morphology and DNA-degradation patterns. 
5.Low and moderate bilirubin concentrations induced excitotoxic cell death in NT2-N 
neurons primarily as caspase-independent apoptosis. Inhibition of excitotoxicity with the 
NMDA receptor antagonist MK-801 was more promising than caspase inhibitors in 
preventing cell death. 
6.Bilirubin-mediated apoptosis in NT2-N neurons is executed by excitotoxic and caspase-
mediated pathways which are, at least in part, distinct. Concurrent inhibition of both 
pathways resulted in synergistic protection. 
7.Serum deprivation concomitantly with bilirubin exposure may influence the cell death 
pathways involved. This should be taken into consideration when studying bilirubin-mediated 
injury in vitro.
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ERRATA
In paper II, page 179 in ”Abbreviations”;  “MTT, 3-4[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazoliumbromide”, should read “ MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazoliumbromide”. 
In paper II, page 182 in Figure 5, in the histogram “Undamaged nuclei” and “Control” the 
asterix † is erroneously placed above the column at 6 h, but should in stead be placed over the 
column at 24 h. 
In paper II, page 184 in the first column; “ In a study on cortical neurons from newborn rats 
by Grojean et al (5), 0.4 ȝM  UCB (without added albumin) induced predominantly apoptotic 
cell death (16 % apoptotic versus 8 % necrotic cells at 96 h) “, should read “…..Grojean et al 
(5), 0.5 ȝM  UCB (without added albumin) induced predominantly apoptotic cell death (16 % 
apoptotic versus 12 % necrotic cells at 96 h)”. 
In paper III in “Abbreviations” on page…,  and under “Materials” on the same page “MTT, 3-
4[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide”, should read “ MTT, 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide. 
In paper III errors in the data handling were discovered after publication. The Editors of 
Pediatric Research are informed, and an erratum has been published (Pediatric Research 
2007 62(3):318). In this thesis the erratum and the corrected figures appear in “Publications” 
after paper III.  
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